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ABSTRACT 
Trimethoxy analogs of tripelennamine, diphenhydramine, and 
pheniramine were studied to determine the influences of the tri-
methoxy group on the pharmacological activity of known antihista-
mines. In this investigation, the ability of the parent compounds 
and their analogs to antagonize the histamine-induced contractions 
of guinea pig ilia were studied as well as their effects on the 
systolic blood pressure of male albino rats and on the central 
nervous system of mice as measured by the actophotometer. 
'lhe trimethoxy analogs were comparatively weak competitive 
antagonists of histamine with the exception of N,N,-Diethyl-N'-
(2-pyridyl)-N'-(3,4,S-trimethoxybenzyl) ethylenediamine Dicyclamate 
(De-TMPBZ) and N,N,-Diethyl-N'-(2-pyridyl)-N'-(3,4,5-trimethoxy-
benzyl) ethylenediamine Disuccinate (TMPBZ) which were weak non-
competitive histamine antagonists. The parent compounds and their 
analogs did not significantly alter the systolic blood pressure of 
rats, but they did cause some minor fluctuations which were of 
interest. 
Intraperitoneal injections of pheniramine in mice caused a 
significant increase (P:::0.05) in locomotor activity, but Drna-TMPP, 
a trimethoxy analog of pheniramine, did not significantly alter 
locomotor activity. Injections of tripelennamine produced no 
significant changes in locomotor activity; however, Mor-TMPBZ, a 
trimethoxy analog of tripelennamine caused a significant decrease 
in activity. 
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I. INTRODUCTION 
The 3,4,5-trimethoxyphenyl group frequently occurs in drugs which 
have a pronounced effect upon the central nervous system. For example, 
two chemically different compounds, reserpine and mescaline, both con-
tain a 3,4,5-trimethoxyphenyl group, and both affect the central ner-
vous system. It is therefore suspected, that the trimethoxyphenyl 
group may play an important part in the activity of some centrally 
active drugs. 
DiFazio (1963) synthesized a series of 3,4,5-trimethoxyphenyl 
analogs of known antihistamines, diphenhydramine (Benadryl ®>, tripelen-
namine (Pyribenzamine ~, and pheniramine (prophenpyridamine, Trimeton ~. 
These antihistamines represent three different chemical groups which, 
in addition to their ability to antagonize histamine, have some effect 
upon the central nervous system. It was hoped that the introduction of 
the trimethoxy group would result in a new psychotropic drug. 
'Ihe purpose of this investigation was to elucidate some of the 
pharmacological properties of the parent compounds and their analogs. 
This was accomplished by determining their histamine antagonizing 
abilities, their effects on normal systolic blood pressure, and their 
effects on the central nervous system, as evidenced by changes in loco-
motor activity. 
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II. LITERATURE SURVEY 
A search for drugs with the ability to antagonize the physio-
logical effects of histamine has been going on for many years. The 
first compound shown to have antihistaminic effects was synthesized 
by Fourneau in 1910 and identified as 929 F (thymoxyethyl diethylamine); 
it was one of a series of amines with a phenolic ether function. Its 
antihistaminic effects were described by Bovet and Staub (1937), who 
showed that 929 F effectively protected guinea pigs against several 
lethal doses of histamine, antagonized histamine-induced spasms of 
various smooth muscles and lessened the severity of the symptoms of 
anaphylactic shock. Two years later, staub (1939) described the anti-
histaminic properties of N' ,N 1 -diethyl-N2-phenyl-N2-ethylethylenediamine 
(1571 F), which proved to be more active than any previously reported 
histamine antagonist. However, 929 F and 1571 F were of little 
clinical value because of their high toxicity. This early work of 
Staub and Bovet stimulated a great amount of research in the United 
States with the subsequent discovery of highly effective histamine 
antagonists, such as diphenhydramine (Benadryl ~ by Loew et al. (1945), 
tripelennamine (Pyribenzamine~ by Mayer et al. (1945), and phenir-
amine (prophenpyridamine, Trimeton~ by LaBelle and Tislow (1948). 
According to Loew (1947), antihistamines are capable of dimin-
ishing the following effects of histamine: (1) spasm of smooth muscle 
located in bronchioles, small intestine and uterus; (2) relaxation of 
arteriolar smooth muscle as demonstrated by a depressor response to 
histamine or increased vascularity of a region; (3) increased capillary 
permeability as indicated by wheal formation and (4) dilatation of 
capillaries and other vessels as demonstrated by localized flare 
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reactions. It is generally recognized, however, that antihistamine 
compounds show little or no effect against histamine-induced gastric 
secretion (Loew 1947). The diverse actions of histamine, which are 
antagonized by various antihistamine compounds, indicate a high degree 
of specificity and serve as a basis for an explanation of antihistamine 
activity. 
A. ANTAGONISM OF HISTAMINE-INDUCED SMOOTH MUSCLE SPASM 
(1) Bronchiospasm Usually, antihistamine drugs are selected and 
partially evaluated by determining their effectiveness in alleviating 
severe symptoms of, or preventing death as a result of, bronchiocon-
striction. This condition is easily induced in guinea pigs with hist-
amine, either administered or liberated during anaphylaxis. Friedlaender 
et al. (1946) expressed antihistamine activity by the number of doses 
of histamine (2.0 mg./Kg.) necessary to cause death in a guinea pig 
previously protected by a subcutaneous injection of 3 mg./Kg. of the 
test drug. They reported values of five doses for diphenhydramine and 
thirty-seven for tripelennamine. Using a slightly different technique, 
Winter (1947) calculated the dose of antihistamine necessary to permit 
survival of 50 percent of the guinea pigs receiving intravenous injec-
tions of histamine dihydrochloride, 0.5 mg./Kg. He found that tri-
pelennamine was about twelve times more effective than diphenhydramine. 
In an extensive discussion of the pharmacological properties of tri-
pelennamine, diphenhydramine, and pheniramine, LaBelle and Tislow (1955) 
calculated the therapeutic index of each drug. · (The therapeutic index 
is found by dividing the lethal dose of a drug in 50 percent of the 
animals (LD50 ) by the effective dose of a drug in 50 percent of the 
animals (ED50 ). In both the ED5o and LD50 studies in question, the 
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antihistamines were administered orally to guinea pigs, and in the 
ED50 study, the drug was given one hour prior to an intravenous 
injection of histamine dihydrochloride (1.1 mg./Kg.). These investi-
gations showed that pheniramine had the highest therapeutic index, a 
value of 170 (LD50 277 mg./Kg.; ED50 1.63 mg./Kg.); diphenhydramine 
was next with a therapeutic index of 70 (LD50 284 mg./Kg.; ED50 4 mg./ 
Kg.), followed by tripelennamine with a therapeutic index of 60 (LD50 
155 mg./Kg.; ED50 2.59 mg./Kg.). 
A more specific index of bronchial spasm consists basically of 
determining the minimum effective dose (M.E.D.) of a drug which sig-
nificantly reduces the mortality rate of guinea pigs exposed to a 
lethal dose of an atomized histamine solution. Using this method, 
Sherrod et al. (1947) reported the minimum effective dose of diphen-
hydramine and tripelennamine given intraperitoneally in doses of 
1.5 mg./Kg. and 0.3 mg./Kg. respectively. Kaiser and Ichniowski (1956), 
reporting the ED50 of several antihistamines, also found tripelennamine 
to be significantly more active than diphenhydramine against histamine · 
admini:>tered as an aerosol. 
The minimum dose of histamine antagonist which will protect an 
animal against anaphylactic death has been used as a measure of anti-
histaminic activity. The anaphylactic test, in general, consists of 
sensitizing the animal with a foreign protein, administering varying 
doses of the test drug, and injecting the challenging dose of foreign 
protein. Friedlaender et al. (1946) and Sherrod et al. (1947) using 
diphenhydramine, and Arbesman et al. (1946) and Mayer (1946) working 
with tripelennamine, demonstrated antagonism of the anaphylactic 
reaction in guinea pigs. The prominent feature of anaphylaxis in 
9 
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guinea pigs is bronchioconstriction. It was found that a dose of 
11 mg./Kg. of pheniramine or tripelennamine was sufficient protection 
against anaphylactic death in guinea pigs, while the same dose of 
diphenhydramine was not (LaBelle and Tislow, 1955). When the concen-
tration of antihistamine was reduced to 5.1 mg./Kg., no deaths were 
found with tripelennamine, but several deaths resulted with pheniramine 
or diphenhydramine. 
It is of interest to note that comparatively larger amounts of 
antihistamines are needed to counteract anaphylaxis than are required 
to counteract histamine shock. Loew (1947) attempted to explain this 
phenomenon by assuming that histamine released during anaphylactic 
shock is in more intimate contact with the effector portion of the cell 
and is therefore more effective than administered histamine which must 
be carried by the circulation to the histamine-sensitive cells. 
The most prominent feature of anaphylaxis in dogs is hypotension 
resulting from vasodilation and increased capillary permeability. 
Other symptoms are respiration irregularities, reaction of smooth 
muscle, and nervous disorders. Yonkman et al. (1945) reported that 
tripelennamine diminished hypotension and the other symptoms of ana-
phylaxis in dogs. An absence of mortality when horse serum was in-
jected into twenty-two sensitized dogs pretreated with diphenhydramine 
was observed by Wells et al. (1947), who also noted that nine animals 
or 35 percent of twenty-six animals died. 
(2) Intestinal and Uterine Spasm Most compounds prepared as 
potential histamine antagonists have been evaluated by determining the 
minimum amount which will relax a histamine-induced spasm of an isolated 
strip of guinea pig ileum suspended in Tyrode's solution. Loew et al. 
(1946) studied histamine antagonism on intestinal muscle and found 
that a spaom induced with histamine diphosphate, 8 x io-8 gm./ml., 
was reduced 75 to 100 percent by diphenhydramine, 2 x lo-8 gm./ml., 
whereas atropine was effective only in a higher concentration, about 
1 x lo-6 gm./ml. In 1946, Mayer showed that a dilution of tripelen-
namine, 2 x io-8 gm./ml., was sufficient to prevent the spasmogenic 
action of histamine, 1x10-7 gm./ml., and occasionally, 1x10-6 gm./ml. 
Tripelennamine was also shown to be only weakly antagonistic to the 
spasmogenic action of acetylcholine. LaBelle and Tislow (1955) were 
also interested in the anticholinergic activity of pheniramine and 
diphenhydramine. Their results showed that both drugs were very weak 
antagonists of acetylcholine, an indication that the antihistamines 
are significantly active only in the presence of histamine. 
Schild presented a paper in 1947 which suggested the use of PA:x 
as a measure of drug antagonism in isolated tissue. He defined p~ as 
the negative logarithm to the base ten of the molar concentration of an 
antagonistic drug which will reduce the effect of a multiple dose (x) 
of an active drug to that of a single dose. Thus, if diphenhydramine 
at a concentration of lo-7 molar in the bath fluid reduces the effect 
of two micrograms of histamine to that produced by one microgram of 
histamine, the pA2 of diphenhydramine antagonism of histamine is 7.00. 
An advantage of using p~ is that some indication of the nature of the 
antagonism can be seen by calculating the difference between pA2 and 
pA10 • Marshall (1955) used Schild's method to determine the pA2 and 
pA10 of diphenhydramine, tripelennamine, and pheniramine antagonism of 
histamine. His pA2 values were: (1) diphenhydramine 8.14; (2) tri-
pelennamine 9.00 and (3) pheniramine 7.82. He concluded from his data 
ll 
that diphenhydramine and tripelennamine probably antagonize histamine 
by competitive inhibition, while pheniramine is definitely a competi-
tive inhibitor. Later work by Van Rossum (1963), using a modification 
of Schild's technique, showed diphenhydramine to be a competitive his-
tamine inhibitor with a p~ value of 7. 70. 
Sherrod et al. (1947), using anesthetized dogs, showed that a 
histamine-induced intestinal spasm was blocked by tripelennamine and 
diphenhydramine. The ability of these antihistamines to reduce smooth 
muscle tonus, or spontaneous motility, in intact dogs was also noted. 
'Ihey found that tripelennamine, when injected intravenously, stimulated 
intestinal and uterine activity, whereas diphenhydramine partially 
decreased tonus and motility of the . intestine. 
The demonstration of antihistamine antagonism of the oxytocic 
action of histamine on the uterus, has been very difficult, because 
many of the common antihistamines exhibit a spasmogenic action. Accord-
ing to Mayer (1946), tripelennamine administered alone has the ability 
to effect contraction of an isolated guinea pig uterus; however, tri-
pelennamine will modify the contractions brought about by histamine to 
such an extent that antihistamine activity must be concluded. Sherrod 
et al. (1947) showed that tripelennamine, injected intravenously into 
anesthetized dogs, was capable of effecting contractions of the uterus, 
while the same dose of diphenhydramine failed to do so. Both drugs 
had the ability to antagonize the spasmotic effect of injected hista-
mine. 
From the experimental data concerning antihistamine action on 
smooth muscle, it may be concluded that antihistaminic drugs do not 
prevent spasms nor exert a prominent spasmolytic effect, except under 
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conditions in which histamine has produced increased tonus, hyper-
motility, or spasm. This type of evidence is often used as proof 
that antihistamines are specific antagonists of histamine and not 
general spasmolytics. 
B. ANTAGONISM OF THE VASCULAR EFFECTS OF HISTAMINE 
In most carnivores, the intravenous injection of small amounts of 
histamine precipitates a rapid, transient hypotension due primarily 
to arteriolar dilatation and some capillary dilatation. Sherrod et al. 
(1947), using anesthetized dogs, found that intravenous doses of 
30 mg./Kg. of tripelennamine and diphenhydramine diminished the de-
presser action of histamine to the same degree (~.~., 55 percent). 
LaBelle and Tislow (1955) also use~ dogs and showed a depression of 
the effects of histamine in animals pretreated with 8 mg./Kg. of either 
diphenhydramine, tripelennamine or phenirami:ne.· From the data, it 
would appear that these drugs possessed equal potency in regard to 
antagonizing the depressor effect of histamine in dogs even though 
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their ability to antagonize the bronchioconstrictive action of histamine 
in g~_nea pigs varied significantly. The work of Loew et al. (1946) 
and Wells et al. (1946), however, showed that the percent inhibition of 
the depressor action of histamine varied only slightly when the dose 
of diphenhydramine was significantly varied. 
This antagonism of the hypotensi ve effect of histamine was not 
attributable to an atropine-like action, since Sherrod et al. (1947) 
reported that tripelennamine was unable to diminish the depressor 
effects of acetylcholine. Loew et al. (1946) demonstrated that intra-
venous injections of diphenhydramine decreased the depressor effect 
of histamine and were also effective in reducing but not abolishing 
the depressor effect of acetylcholine. The anticholinergic action 
of diphenhydramine was shown to be relatively weak, since it required 
only 1/100 as much atropine to duplicate the effect. 
When the antihistamine drugs are injected intravenously, they 
cause only slight effects in normal blood pressure. Cats which had 
been injected intravenously with tripelennamine in doses of 10 to 200 
micrograms showed only minor fluctuations in blood pressure after the 
smaller doses, and a slight sustained rise after the larger doses 
(Yonkman et al. (1946). Loew et al. (1946) reported a 6 to 10 percent 
drop in blood pressure for about one minute, followed by an 8 to 10 
percent increase in blood pressure lasting three to eight minutes in 
dogs injected with low doses of diphenhydramine. When the dose of 
diphenhydramine was increased to 3 mg./Kg., the diphasic alterations 
in blood pressure were similar but of greater magnitude. According 
to LaBelle and Tislow (1955), pheniramine administered at a rate 
faster than 6 mg./minute produced a transient fall in blood pressure, 
followed by a rise in blood pressure in dogs. Neither the pressor 
nor the depressor responses of the antihistamine drugs were of suf-
ficient degree or duration to suggest a relationship to their antag-
onism of histamine, which lasted for one to two hours. 
C. ANTAGONISM OF LOCALIZED CUTANEOUS RESPONSES TO HISTAMINE 
The experimental studies concerning antihistamine antagonism as 
related to capillary dilatation and increased capillary permeability 
are almost wholly concerned with cutaneous responses to histamine. 
An intradermal injection of histamine causes a localized edema or 
wheal formation, which is mainly the result of increased capillary 
permeability independent of nervous factors. The accompanying flare, 
however, is mainly dependent on vasodilation produced through reflex 
action. Loew (1950) felt that any analysis of the wheal and flare 
responses, as influenced by antihistamine drugs, must include con-
sideration of influences on increased capillary permeability, vaso-
constriction, vasodilation and the nervous factors related to the 
flare. 
In the preceding section, it was observed that tripelennamine, 
diphenhydramine, and pheniramine did not produce a significant vaso-
dilator or vasoconstrictor effect in intact animals. It therefore 
seems unlikely that changes in vascularity induced by antihistamines 
would account for a decrease of the wheal and flare response to hist-
amine. However, Haley and Harris (1949) found some interesting results 
in their experiments on the capillary effects of antihistamines. 'Ihey 
studied the effects of antihistamines topically applied to rat mesa-
appendix, and their results showed that tripelennamine at the concentra-
tion of 0.01 moles, pheniramine at 0.01 moles, and diphenhydramine at 
· 0.001 moles all produced some vasoconstriction. They felt this vaso-
constrictor response might in part account for antihistamine antagonism 
of histamine-induced capillary dilatation. 
Diphenhydramine (Leavitt and Code; 1947), tripelennamine (Mayer, 
1946), and pheniramine (LaBelle and Tislow, 1955) have been shown to 
possess some local anesthetic capabilities. The local anesthetic pro-
perties of all three antihistamines were studied by LaBelle and Tislow 
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(1955) by means of the blink reflex in guinea pigs . They found diphenhy-
dramine to be the best local anesthetic of the three. Tripelennamine and 
pheniramine exhibited some local anesthetic properties, but to a lesser 
degree than diphenhydramine. In a clinical study involving over 2000 
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patients, Fitzpatrick and Orr (1955) showed that a 2 percent solution 
of tripelennamine was a safe and potent urethral anesthetic. Very 
few failures of anesthetic activity were recorded. Therefore, it 
would seem that injection in localized areas or topical application 
of suitable quantities of these antihistamines could affect cutaneous 
reactions by means of a local anesthetic action. 
Experiments by Leavitt and Code (1947) demonstrated that both 
diphenhydramine and procaine given intradermally in man definitely 
diminished cutaneous responses to histamine. However, after the 
local anesthetic effect of both drugs had subsided, some other action 
of diphenhydramine persisted and diminished the cutaneous reaction to 
histamine. It therefore seemed likely that the local anesthetic acti-
vity of diphenhydramine only partially accounted for its inhibitory 
influence on cutaneous reaction to histamine. Aaron and Abramson (1947) 
introduced tripelennamine and procaine into human skin by iontophore-
sis one and one-half hours before introducing histamine. Tripelennamine 
inhibited the histamine wheal and flare reaction, but procaine did not. 
This indicated that the action of tripelennamine was a result of antag-
onism of histamine and not a local anesthetic action. 
The oral administration of diphenhydramine by Friedlaender and 
Feinberg (1946) and of tripelennamine by Arbesman et al. (1946) to 
humans frequently diminished the effects of intracutaneous injections 
of histamine. 'Ihe highest incidence and degree of supression of 
cutaneous responses to histamine occurred when threshold doses of 
histamine were injected in subjects treated with antihistamine drugs. 
D. CENTRAL NERVOUS SYSTEM EFFECTS 
The antihistaminic drugs have been used clinically to relieve the 
discomforts of seasonal hay fever, perennial vasomotor rhinitis, 
asthma, ur"i.;icarial dermatoses, allergic dermatitis, and serum reactions. 
Feinberg (19.5G, in a review of the clinical uses of antihistamines, 
pointed out that these drugs were capable of symptomatic relief only 
and did nothing to relieve the cause of the abnormality. The clinical 
usefuJness of these compounds varied with patients, depending on their 
susceptibility to the drug's side effects. One of the most important 
side effects of antihistamine drugs is their action on the central 
nervous system. They can cause stimulation resulting in restlessness, 
nervousness, or insomnia, but most frequently they cause depression 
resulting in sedation. Tripelennamine, pheniramine, and especially 
diphenhydramine are capable of producing somnolence in some persons. 
This condition seems to be the result of some type of depression of 
the central nervous system, independent of their histamine antagonism. 
Loew et al. (1946), in his original study of the pharmacological 
properties of diphenhydramine, observed no drowsiness in dogs which 
had received 10 mg./Kg. subcutaneously. Winter et al. (1948) obtained 
similar results in mice, rats, dogs, guinea pigs and monkeys. When 
diphenhydramine was given to mice in sublethal amounts, Graham (1947) 
observed powerful central excitement and incoordination. LaBellE? and 
Tislow (19.5.5), studying the effects of pheniramine, found that oral 
doses of about 12 mg./Kg. produced slight drowsiness in dogs. When 
the dose was increased, they noted anorexia, decreased and slower 
responses, tremors of the head, apprehension, hypersensitivity and 
jumpiness. The dogs often lost their ability to stand and frequently 
had mild convulsions. The symptoms leading to their deaths were alike. 
'Ille animals suddenly went into tonic-clonic convulsions with opistho-
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tonus, while their bodies were in tremor. LaBelle and Tislow noted 
that the main symptoms of death pointed to involvement of the central 
nervous system. Mayer et al. (1946) observed no drowsiness as a re-
sult of low doses of tripelennamine, but when given in toxic amounts, 
it caused the animals to become excited and convulsive. 
The measurement of drowsiness in experimental animals is very 
difficult, if not impossible, to quantify. Such is not the case with 
humans, because they have the advantage of being able to explain their 
condition to the investigator. Beck (1947) made note of the common 
side effects in patients receiving diphenhydramine or tripelennamine. 
The most common side effects were depression of the C.N.S. resulting 
in drowsiness, lassitude and inability to concentrate. Pearson (1957) 
made a study of the psychomotor effect of diphenhydramine on air force 
trainees. He found that subjects who received 50 mg. of the drug were 
unable to perform a practiced test as well as did placebo control sub-
jects. Pearson concluded that the effects of diphenhydramine were such 
that they should not be used in circumstances where perceptual motor 
skills are required. 
Numerous workers have tried to study the C.N.S. actions of the 
antihistamines with varying degress of success. Winter (1948) studied 
the effects of diphenhydramine and tripelennamine on the sedative 
action of hexobarbital in mice. He found that the mean waking time was 
prolonged about 10 percent by tripelennamine and about 40 percent by 
diphenhydramine. He concluded that whatever potentially sedative 
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effect antihistamines might have in animals was masked by a coexisting 
excitatory effect, and that, in low doses, the two effects might cancel 
each other. In 1952, Way and Herbert reported that sodium pentobarbital 
increased the intraperitoneal LD50 of tripelennamine and diphenhydra-
mine in rats. It did not affect the death rate significantly in 
animals overdosed orally with diphenhydramine and tripelennamine, 
although convulsions were less severe when preceded by the barbiturate. 
They also reported that when the animals were injected with a low dose 
of sodium pentobarbital (30 mg./Kg.) as an antidote, they died from 
convulsions, whereas a higher dose (60 mg./Kg.) caused death from 
respiratory depression. To explain the difference in causes of death, 
Way and Herbert suggested that the degradation products of the anti-
histci.mines, which are present in greater amounts after oral adminis-
tration, may enhance the actions of pentobarbital and contribute to its 
overall toxicity. 
Lightstone and Nelson (1954) showed that diphenhydramine and tri-
pelennamine significantly prolonged pentobarbital sleeping time in rats. 
In an attempt to explain this effect, they suggested that the drugs 
did not seem to interfere with liver detoxification of pentobarbital. 
When there was a high enough plasma concentration of the barbiturate, 
it appeared that diphenhydramine caused an increase in the rate of 
entrance of pentobarbital into the brain. They concluded that the 
mechanism by which diphenhydramine and tripelennamine prolonged pento-
barbi tal sleeping time was independent of their common side effects. 
Another method used to determine the C.N.S. effects of the anti-
histamines is the use of trained animals. Winter and Flataker (1951) 
trained rats to climb a vertical rope. The climbing time was noted, 
as well as the behavior of the animals. In general, diphenhydramine 
and tripelennamine gave evidence of cerebral depression and muscular 
incoordination resulting in failure or prolongation in the climbing 
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time of the trained rats. Tripelennamine seemed to have a more pro-
nounced effect on the behavior of the trained rats than that of di-
phenhydramine. The depressant effects of diphenhydramine and tripel-
ennamine were counteracted by the administration of amphetamine or 
caffeine, which suggested to the investigators that the site of action 
was probably the cerebral cortex. 
In order to gain more information about the effects of antihista-
mines in the C.N.S., the locomotor activity of rats injected with 
tripelennamine and diphenhydramine has been studied. Heinrich (1951) 
found that administration of diphenhydramine, 22.8 mg./Kg./day, or 
tripelennamine, 21.6 mg./Kg./day, in the diet had no effect on the 
spontaneous running of adult rats in activity cages. A more complete 
study was made by Baird and Boyd (1954) who placed drug-treated rats 
in Wahman vertically-revolving drums and recorded locomotor activity. 
They administered tripelennamine orally and subcutaneously in amounts 
from 1 mg./Kg. to lethal doses and found that tripelennamine had a 
statistically insignificant effect on locomotor activity. They also 
found that subcutaneous injections of diphenhydramine in doses up to 
25 mg./Kg. had no effect on locomotor activity. When they gave diphen-
hydramine orally in doses of 100 and 200 mg./Kg., significant increases 
in activity were noted. Doses of 200 mg./Kg. caused convulsions and 
death in 80 percent of the animals. Therefore, Baird and Boyd con-
cluded that diphenhydramine in toxic doses stimulated the C.N.S. and 
caused an increase in locomotor activity. 
It can be said that all antihistamines possess, in varying degrees, 
the pharmacological properties discussed in the preceding pages. They 
all have the ability to antagonize most of the pharmacological actions 
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of histamine. Antihistamines also reduce the intensity of allergic 
and anaphylactic reactions, and it is this property that serves as 
the basis for their major therapeutic applications. The C.N.S. 
effects of antihistamines have proven to be interesting and somewhat 
baffling to many scientists. It was primarily the ability of anti-
histamines to affect the C.N.S. that led to the synthesis of the 
trimethoxy analogs of tripelennamine, diphenhydramine, and pheniramine, 
which are discussed in the following pages. 
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III. INVESTIGATION 
A. OBJECTIVES 
This study was concerned with the determination of some of the 
pharmacological properties of trimethoxyphenyl analogs of tripelen-
namine, diphenhydramine, and pheniramine. The experimental compounds 
were studied by observing their effects on the following parameters: 
(1) antagonism of histamine-induced contractions of isolated guinea 
pig ileum; (2) systolic blood pressure of male albino rats: and (3) 
exploratory activity of male albino mice. 
The ultimate goal of this investigation was to provide informa-
tion concerning the activity and the mechanisms of action of the 
parent compounds and their analogs, thus enabling the pharmaceutical 
chemist to more accurately predict the effects of trimethoxyphenyl 
substitutions on known compounds. 
B. MATERIALS AND METHODS 
(1) Compounds The experimental compounds were synthesized by 
Dr. L.D. DiFazio (1963), Department of Pharmaceutical Chemistry, 
University of Rhode Island. Glass distilled water was used as the 
solvent throughout the study since the synthesized compounds, as well 
as the parent compounds, diphenhydramine hydrochloride (Benadryl ~1, 
pheniramine maleate (prophenpyridamine, Trimeton ~2 , and tripelen-
1 Kindly supplied by Dr. A.G. Bratton, Parke-Davis Laboratories, Ann 
Arbor, Michigan 
2 Kindly supplied by Dr. R.E. Thompson, Schering Laboratories, Bloom-
field, New Jersey 
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namine hydrochloride (Pyribenzamine~1 , were all available in the form 
of water soluble salts. 
The trimethoxyphenyl analogs of tripelennamine are listed below. 
a. N,~-Dimethyl-N'-(2-pyridyl)-N'-(3,4,S-trimethoxybenzyl) 
ethylenediamine Disuccinate (TMPBZ), 
b.fi-(4-Morpholino)-N-(2-pyridyl)-N-(3,4,S-trimethoxybenzyl) 
ethylamine Dicyclamate (Mor-TMPBZ), 
c. N,N,-Diethyl-N'-(2-pyridyl)-N'-(3,4,S-trimethoxybenzyl) 
ethylenediamine Dicyclamate (DE-TMPBZ), 
d. ,8-(1-Piperidino)-N-(2-pyridyl)-N-(3,4,S-trimethoxybenzyl) 
ethylamine Dicyclamate (Pip-TMPBZ), 
e. p-~-Pyrrolidino)-N-(2-pyridyl)-N-(3,4,S-trimethoxybenzyl) 
ethylamine Dicyclamate (Pyl-TMPBZ). 
The trimethoxyphenyl analog of diphenhydramine is 2-(3,4,S-trimethoxy-
benzhydryloxy)-N,N-dimethylethylamine Succinate (TMBD). The trimethoxy-
phenyl analogs of pheniramine are: 
a. l-(2-pyridyl)-1-(3,4,S-trimethoxyphenyl)-3-dimethylamino-
propane Cyclamate (TMT), 
b.W-Dimethylamino-3,4,S-trimethoxypropiophenone Hydrochloride 
(Dma-TMPP). 
'Ihe structural formulas of all the above compounds are shown in 
Figures I-III. 
(2) Isolated Tissue Study The ability of the parent compounds 
and their analogs to antagonize histamine-induced contractions of 
intestinal smooth muscle was studied on isolated guinea pig ileum. 
Each guinea pig2 was deprived of food twenty-four hours before being 
sacrificed. The ileum was removed and a section l.S-2.0 centimeters 
1 Kindly supplied by Dr. J. Cooper, CIBA Laboratories, Summit, New Jersey 
2 Purchased from Albino Farms, Red Bank, New Jersey 
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FIGURE 2 
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FIGURE 3 
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was suspended in a tissue bath containing thirty milliliters of 
aerated Tyrode 1 s solution. The Tyrode 1 s solution was maintained at 
J7° centigrade by suspending the entire tissue bath in a thermostat-
ically-regulated water bathl. The contractions of the tissue were 
recorded on a slowly-moving sooted kymograph by means of an isotonic 
writing lever. 
TABLE 1 
SEQUENCE OF HISTAMINE DOSES ADDED FOR 
CUMULATIVE DOSE-RESPONSE CURVES 
The amount to be added 
to the tissue bath 
Total molar concentration 
in the tissue bath 
Ml. 
O.OJ 
0.06 
0.21 
0.06 
0.21 
0.06 
0.21 
etc. 
Molar Concentration x 10-8 
1 
J 
10 
JO 
100 
JOO 
1000 
etc. 
\ 
Cumulative dose-response curves, as described by Van Rossum and 
Van Den Brink (196J), were made with each experimental compound. To 
make these curves, increasing amounts of histamine diphosphate were 
added to the tissue bath until a maximum contraction was effected. 
A contraction was considered maximum when subsequent doses of histamine 
1 Precision Scientific Company, Chicago, Illinois 
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resulted in no further contraction of the ileum (Figure 4). The 
histamine was added to the bath in a stepwise sequence of one-half 
log10 intervals (Table 1). Whenever possible, the total amount of 
added solution was kept below l.S milliliters (~.~., S percent of the 
tissue bath volume). 
In order to observe the antagonistic ability of the antihistamines 
and their analogs, it was necessary to make dose-response curves of 
histamine alone, as well as dose-response curves of histamine in the 
presence of the antagonists (Figures 4 and 6). The experimental drugs 
were allowed to equilibrate for two minutes in the tissue bath before 
histamine was added. Ea.ch drug was tested at three dose levels on 
three different guinea pig ilia. 
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'Ihe dose-response curves were evaluated by measuring the contrac-
tions in millimeters produced by each cumulative dose of histamine and 
expressing it as a percent of the maximum height of the completed curve. 
The percentages were plotted on a linear scale as millimeters on the 
ordinate (100 percent equal 100 millimeters) and the logarithms of the 
doses were plotted on the abcissa, using thirty millimeters for one 
log10 interval (Figures S and 7). The theory and method used to evalu-
ate the dose-response curves is described by Van Rossum (1963) and is 
briefly discussed below. 
a. Evaluation of Histamine Cumulative Dose-Response Curves 
Histamine is a stimulant drug and is therefore referred to as an 
agonist. It is generally believed that agonists produce a stimulus as 
a result of receptor occupation and in this way produce an effect. 
Stimulant drugs have both an affinity for the receptor site and an 
intrinsic activity, and are characterized mainly by these properties. 
The affinity of the agonist for the receptor site is often used 
as an estimate of drug potency and is expressed as a pD2 value. pD2 
is the negative logarithm of the molar dose necessary to produce a 
response that is 50 percent of the maximum effect. In order to find 
the pD2 values of histamine, each dose-response curve was plotted 
according to the previously described procedure. The logarithm of the 
molar dose of histamine required to induce a 50 percent response was 
then read from the graph and converted to its negative logarithm. 
b. Evaluation of Competitive Antagonists Competitive antagonists 
are inactive as such. They have an affinity for a specific receptor 
site but have no intrinisic activity; therefore, they do not have the 
ability to generate a stimulus. In. order to study the effects of a 
competitive antagonist, it must be combined with a stimulant drug 
(~.~., an agonist). A dose-response curve of the agonist in the pre-
sence of a given concentration of the competitive drug has a shape 
essentially identical with the curve when the antagonist is absent. 
When the competitive drug is present, a 50 percent response can be 
reached only with a higher concentration of the agonist; therefore, 
the curves are shifted to the right on the log dose-axis (Figures 5 and 
7). This shift (x), is equal to the concentration of the agonist in 
the presence of the antagonist (AB) divided by the concentration of the 
agonist in the absence of the antagonist, (A0 ). 
x = A~A0 
The value of x can be used as an estimate of drug potency, which, 
in turn, is related to the affinity of the antagonist for the receptor 
site. The affinity of the antagonist is expressed as the negative 
logarithm of the molar concentration that caused the shift x, and is 
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designated PA:x· The pAx value is then converted to a pA2 value, which 
is the neg~tive logarithm of the molar concentration of the antagonist 
that will cause a shift of a factor 2. 'Ihe relationship between PA:x 
and pA2 is: 
pA2 = p~ + log(x-1) 
The experimental procedure for competitive antagonists consisted 
of alternating histamine dose-response curves with dose-response curves 
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of histamine in the presence of the experimental drug (Figures 4 and 6). 
The logarithms of the molar concentrations of histamine used to com-
plete each dose-response curve were then plotted according to the pre-
viously described procedure. A
0 
and AB were read from these graphs and 
x and pAx were calculated. Once x and pAx were known, pA2 was easily 
determined. 
c. Evaluation of Non-Competitive Antagonists Non-competitive 
antagonists, like competitive antagonists, are inactive as such. 
These drugs do not have an affinity for the specific receptors of the 
agonist but interact with different receptors and, thereby, influence 
stimulus formation or stimulus effectuation. It can be seen from 
Figures 8 and 10, that the main action of the non-competitive antagonist 
is a depression of the dose-response curve of the agonist. This depres-
sion can be used to estimate the affinity of the antagonist for its 
receptor site, and is also a measure of the potency of the drug. The 
negative logarithm of the molar concentration that causes a depression 
(x) of the dose-response curve is called pD'x· pD 1 is always converted 
x 
to pD 1 2, which is the negative logarithm of the molar concentration of 
the non-competitive antagonist that causes a depression of 50 percent. 
--- -------------
The relationship of pD'x to pD 1 2 is: 
pD' = pD' + log(x-1) 2 x 
In this study, the pD 1 2 values were found by dividing the maximum 
height of the histamine dose-response curve in the presence of the 
antagonist (EAmB,) by the maximum height of the histamine dose-response 
curve in the absence of the antagonist (EArn). By knowing this ratio, 
it was possible to calculate x and pD' since: 
x 
EArnB' 100 
EArn x 
pD 1 2 was then calculated by following the proper formula. 
(3) Blood Pressure Study The effects of diphenhydramine, tripel-
ennamine, pheniramine, and their trimethoxyphenyl analogs were measured 
on systolic blood pressure by cannulation of the carotid artery. Ma.le 
albino rats of the Sprague-Dawley strain1 weighing 222-293 grams were 
used. The recording system consisted of a mercury manometer connected 
to a glass cannula via a fluid bridge of 0.9 percent saline. The blood 
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pressure fluctuations were recorded on a slowly-moving sooted kymograph. · 
All the animals used in this study were deprived of food for twenty-four 
hours before they were anesthetized with 1.1 gm./Kg. of urethan, in-
jected intraperitoneally. To prevent the blood from clotting in the 
cannula, 0.1 milliliters of heparin sodium, 1:1000, was put into the tip 
of the cannula. 
All the compounds studied were dissolved in glass distilled water 
and were injected intravenously via the femoral vein. The doses of the 
drugs were calculated on a molar basis in order to allow for a more 
1 Charles River Breeding Farm, North Wi.lmington, Massachusetts 
accurate comparison of the parent compounds to their analogs. Each 
rat was given only on injection of a drug before it was discarded. 
After a compound was injected, the duration and degree of any 
change in the blood pressure was recorded. All drug-induced increases 
or decreases in blood pressure were measured as mmHg and were reported 
as a percent change from the normal blood pressure. The duration of 
a response was measured in minutes and seconds using a Franz Kymo 
Timer1 • The response was considered ended when the blood pressure 
returned to normal, ± 5 mm Hg. 
(4) Activity Study Male albino Charles River2 mice weighing 
18-24 grams were used for the activity study. The animals were 
housed in a soundproof, windowless room maintained at about 50 per-
cent relative humidity with a constant temperature of 20° ± 1° centi-
grade. The room was artificially lighted daily from 7:00 a.m. to 
6:00 p.m. Each animal was fed four grams of Purina Rat Chow3 daily 
at 3:30 p.m. and had unlimited access to water. All the mice were 
allowed to acclimate to the room and feeding schedule for ten days 
before the study began. 
Four multibeam actophotometers4, located in the above described 
room, were employed to determine the effect of tripelennamine, phenira-
mine, Mor-TMPBZ, and Dma-TMPP on the exploratory activity of mice. 
1Franz Manufacturing Company, New Haven, Connecticut 
2
charles River Breeding Farm, North Wilmington, Massachusetts 
)Ralston Purina, St. Louis, Missouri 
4Metro Scientific, Inc., Carle Plase, Long Island City, New York 
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The actophotometer consists of a circular cage with a grid floor. 
Twelve equally spaced holes are located about one centimeter from 
the grid floor around the inside diameter of the cage. From these 
holes, six light beams radiate through a red filter and across the 
cage to activate their respective photoelectric cell. When a light 
beam is broken, it causes a digital counter located in an adjacent 
room to advance one unit. In this manner, it is possible to obtain 
an estimate of exploratory activity per unit time. 
The light beams and photocells were adjusted for maximum sensiti-
vity by varying the angle of incidence of light to the photocell and by 
adjusting the voltage to the counter relay and photocell. Mendillo 
(1965) found that each cage had its own sensitivity characteristics, 
resulting in varying total counts per unit time from one cage to 
another. Therefore, the experiment was designed so that data from 
both vehicle-treated and drug-treated animals were obtained from the 
same cages. 
Table 2 outlines the experimental design used in this study and 
represents one run. In each run, three groups of mice were used with 
four mice per cage. As each animal was used only once, a total of 
forty-eight mice were used in one run. The entire study consisted of 
six runs, which were conducted on three consecutive days between the 
hours of 9:00 a.m. and 3:00 p.m. Following injection with a drug or 
vehicle, ten minutes was allowed for systemic absorption. The animals 
were then placed in their respective activity cages. Transferring the 
mice and turning on the counters took approximately thirty seconds. 
Total counts per cage for thirty minutes as well as incremental counts 
per ten minutes and fifteen minutes were recorded. 
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TABLE 2 
EXPERIMENTAL DESIGN OF THE ACTIVITY STUDY 
CAGE I II III IV 
Group I Vehicle-Treated Vehicle-Treated Vehicle-Treated Vehicle-Treated 
Group II Vehicle-Treated Pyribenzamine Mor-TMPBZ Mor-TMPBZ 
7.6 x lo-2M/Kg. 7. 6 x l0-2M/Kg. 1.52 x lo-lM/Kg. 
Group III Vehicle-Treated Pheniramine Dma-TMPP Dma-TMPP 
1 x lo-lM/Kg. 1 x lo-lM/Kg. 2 x lo-1M/Kg. 
'Ihe vehicle-treated animals received an intraperitoneal injection of 0.2 ml. of glass-distilled 
water. 
All drugs were dissolved in glass-disstilled water and were injected intraperitoneally in an 
approximate volume of 0.2 ml. 
,_ .... ,.~:,,;;.~"Uliliillllf: ··' 
VJ 
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The data were analyzed by comparing the counts per unit time from 
the drug-treated animals to their respective controls. The comparisons 
were evaluated by calculating the student's "t" value (Snedecor 1956). 
The following comparisons per unit time were made: (1) incremental 
counts per ten minutes; (2) incremental counts per fifteen minutes; 
and (3) total counts per thirty minutes. 
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IV. RESULTS 
All experimental results are contained in this section. 
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FIGURE 4 
CUMULATIVE DOSE-RESPONSE CURVES OF HISTAMINE 
ON THE GUINEA PIG ILEUM IN THE PRESENCE 
AND ABSENCE OF DIPHENHYDRAMINE 
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Note that as the concentration of diphenhydramine (a known 
competitive antagonist) is increased, a higher dose of 
histamine is needed to reach the same level. 
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FIGURE 5 
CUMULATIVE DOSE-RESPONSE CURVES AS CALCULATED FROM FIGURE 4 
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Note the progressive shift of the dose-response curves as 
induced by the competitive antagonist. From this shift, 
the drug 1 s affinity toward the receptor site can be calcu-
lated as a pA2 value. 
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EXPERIMENT NO. 
Diphen. I I 6 
8 
8 
10 
1 
3 
Diphen. TI I s 
7 
7 
9 
9 
11 
TABLE 3 
DIPHENHYDRAMINE HYDROCHLORIDE ANTAGONISM TO HISTAMii-JE-INDUCED 
CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
RESPONSE TO AGONIST 
MAX. 
RESP. 
(mm) 
121 
118 
118 
119 
113 
109 
130 
129 
129 
122 
122 
112 
Ao 
S.4xlo-S 
4.2xio-S 
4.2xio-S 
3.2xio-S 
3.4x10-S 
4.2xio-S 
5.3xio-S 
4.8xio-S 
4.8xio-S 
S.4x10-S 
S.4xlo-S 
4.Sxio-5 
pD2 NO. 
5.73 7 
S.62 7 
S.62 9 
s.so 9 
s.s3 2 
S.62 2 
s. 72 6 
S.68 6 
S.68 8 
5.73 8 
S.73 10 
S.65 10 
RESPONSE TO AGONIST PLUS ANTAGONIST 
B. 10-q 
lOxlo-8 
lOxlo-8 
3oxio-8 
3oxio-8 
3xio-8 
3xio-8 
3xio-8 
3xio-8 
lOxl0-8 
10x10-~ 
3oxio-
30x10-8 
MAX. 
RESP. pAx 
(mm) 
AB 
120 1.00 4.4xlo-~ 
120 7.00 2.7xio-6 116 6.So 9.4xlo-6 116 6.So s.sxio-5 115 7.So 4.8xio-6 115 7. 50 1. lxlO-
130 7.So LSx10-~ 
130 7.So 1. 3xl0-6 
128 7.00 3.4x10-6 
128 7.00 4,3x10-6 122 6.So 2. 6xio-
122 6.So l.8x10-7 
p~ 
7 .86 
7.73 
7.83 
7. 71 
7.56 
7. 71 
7.76 
7. 71 
7.78 
7.84 
8.17 
8.09 
\.,V 
'-0 
~:Zii 
TABLE 3 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMENT NO. 
Diphen. IIT I 6 
8 
8 
10 
10 
12 
MAX. 
RESP. 
(mm) 
144 
146 
146 
147 
147 
142 
A 
0 
5.4xlO-; 
5.4xio-
5 5.4xlo-
5 5.oxio-
5 5.oxio-
5 5.3xio-
pD2 
5,73 
5,73 
5,73 
5.70 
5,70 
5. 72 
NO. = The number of the curve being measured. 
NO. B. 10-q 
7 3xio-8 
7 3x10-8 
9 lOxlo-8 
9 lOxlO-~ 
11 JOxlO-
11 30xlo-8 
MAX. 
RESP. pAx 
(mm) 
147 7,50 
147 7,50 
148 7.00 
148 7.00 
145 6.50 
145 6.50 
A = The molar dose of the agonist to produce a 50% response. 
PB2 = The negative (-) log of the dose necessary to produce a 50% response. 
B. 10-q = The molar concentration of the antagonist. 
AB 
4 -6 1. xlO 6 L4xl0-
3.lxlo-6 2.6x10-~ 
2.ox10-6 7.5xio-
PAx: = The negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
pAx = (q - log B). 
pA2 
7. 68 
7.68 
7.67 
7.62 
7.56 
7.62 
AB = The molar dose of the agonist which produces a 50% response in the presence of the antagonist. 
pA2 = The negative (-) log of the molar concentration of antagonist which causes a shift of a factor 2; 
pA2 = pAx + log(x-1); x = A0 ;AB. Diphen. = Diphenhydramine hydrochloride. 
g 
FIGURE 6 
CUMULATIVE DOSE-RESPONSE CURVES OF HISTAMINE 
ON THE GUINEA PIG ILEUM IN THE PRESENCE 
AND ABSENCE OF PIP-TMPBZ 
Note that as the concentration of Pip-TMPBZ is increased, a 
higher dose of histamine is needed to reach the same level. 
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FIGURE 7 
CUMULATIVE DOSE-RESPONSE CURVES AS CALCULATED FROM FIGURE 6 
PIP-TMPBZ I 
X lo-5M 
LOG DOSE OF HISTAMINE IN MOLES 
Note the progressive shift of the dose-response curves as 
induced by the competitive antagonist. From this shift, 
the drug's affinity toward the receptor site can be calcu-
lated as a p~ value. 
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TABLE 4 
PIP - TMPBZ ANTAGONISM TO HISTAMINE-INDUCED CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
MAX. MAX. 
EXPERIMENT I NO. RESP. A pD2 NO. B. 10-q RESP. PAx AB (mm) 0 (mm) 
Pip-TMPBZ I I 1 132 6.3xio-5 5.80 2 3xio-5 132 4.5o 8.2xio-~ 
3 134 5.9xio-5 5. 77 2 3xio-5 132 4.5o 7.lxlo-6 3 134 5.9xio-5 5. 77 4 lOxlo-5 131 4. oo 1. ox10-5 5 134 5.6xio-~ 5. 75 4 lOxlo-5 131 4.00 9.5x10-6 5 134 5.6x10-5 5. 75 6 3oxio-5 122 3.50 2.oxio-6 7 132 5.4xio- 5. 73 6 3ox10-5 122 3. 50 1. 8x10-
Pip-TMPBZ TI I 1 119 4.oxio-~ 5.60 2 lOxlo-5 114 4.00 4.0x10-5 
3 110 4.5xlo-5 5. 65 
2 lOxlo-5 114 4.00 5.4x10-g 
3 110 4.5x10- 5. 65 4 3ox10-5 101 3.50 l.lxlO-6 5 104 4.7xio-5 5.67 4 30xlo-5 101 3.50 Llxlo-
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pA2 
3.91 
3. 72 
3.85 
3.81 
3. 91 
3.86 
2.59 
3.22 
3. 68 
3.65 
~ 
VJ 
~ 
TABLE 4 - Continued 
RESPONSE TO AGONIST 
EXPERIMENT .I NO. 
Pip-TMPBZ NI 9 
11 
11 
13 
MAX • . 
RESP. 
(mm) 
134 
134 
134 
130 
Ao 
3.ox10-S 
3.4xio-S 
3.4xlo-S 
3.oxio-S 
pD2 
S.48 
S.S3 
S.S3 
S.48 
NO. = The nwnber of the curve being measured. 
NO. 
10 
10 
12 
12 
RESPONSE TO AGONIST PLUS ANTAGONIST 
B. 10-q 
10x10-S 
10x10-S 
3oxio-S 
3oxio-S 
MAX. 
RESP. pA 
(mm) x AB 
130 
130 
118 
118 
4.oo 3.3xio-S 
4.oo 4.4x10-S 
3.So 6.8x10-S 
3.So S.4x10-S 
A = The molar dose of the agonist to produce a SO% response. 
PB2 = The negative (-) log of the dose necessary to produce a SO% response. 
B. lo-q = The molar concentration of the antagonist. 
PAx = The negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
pAx = (q - log B). 
pA2 
3.04 
3.41 
3.So 
3.39 
AB = The molar dose of the agonist which produces a SO% response in the presence of the antagonist. 
pA2 = The negative (-) log of the molar concentration of antagonist which causes a shift of a factor 2; 
pA2 = pAx + log(x-1); x = AafAB• . 
.i::--
.i::--
EXPERIMENT NO. 
Pyri. I I 3 
5 
5 
7 
7 
9 
Pyri. JIT I 1 
3 
3 
5 
5 
7 
TABLE 5 
TRIPELENNAMINE HYDRCHLORIDE ANTAGONISM TO HISTAMINE-INDUCED 
CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
MAX. 
RESP. 
(mm) 
109 
112 
112 
115 
115 
117 
116 
120 
120 
109 
109 
109 
Ao 
4.2xio-~ 
3.6x10-
5 3.6xio-
5 4.7xl0-5 
4.7xl0-5 
4.7xl0-
4.3xlo-5 
5.9xio-§ 
5.9x10-5 
5.3xio-5 5.3xio-5 3.wo-
pD2 NO. 
5.62 4 
5.55 4 
5.55 6 
5.67 6 
5.67 8 
5.67 8 
5.63 2 
5. 77 2 
5. 77 4 
5.72 4 
5. 72 6 
5.53 6 
B. 10-q 
lOxlo-9 
lOxlo-9 
3ox10-~ 
3oxio-
3xlo-9 
3xlo-9 
3xlo-9 
3xio-9 
lOxlo-9 
lOxlo-9 
3oxio-9 
30xlo-9 
MAX. 
RESP. 
(mm) 
116 
116 
115 
115 
115 
115 
119 
119 
123 
123 
114 
114 
pAX AB 
8.oo 2.1x10-~ 
8.00 l.5xlo-6 7.50 3.oxio-5 7.50 5.lxl0-5 
8.5o 8.oxio-5 8.50 8.0xlO-
8.50 8.6x10-~ 
8.50 i.6xio-6 8.00 2.8xio-
8.00 2.3xio-~ 
7.50 8.7x10-6 7.50 3.7xlo-
pA2 
8.60 
8. 52 
8.36 
8.49 
8.31 
8.31 
8.50 
8.27 
8.58 
8.52 
8.69 
8.49 
~ 
\.J1 
TABLE 5 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMENT NO. 
Pyri. m:: I 1 
3 
3 
5 
5 
7 
MAX. 
RESP. 
(mm) 
145 
143 
143 
144 
144 
137 
Ao pD2 
5.Jxlo-5 5. 72 
4.8x10-5 5.68 4.8x10-~ 5.68 
5.4xlo- 5.73 
5.)+xlo-5 5.73 
4.5xio-5 5.65 
NO. = The number of the curve being measured. 
NO. B. 10-q 
2 Jxlo-9 
2 Jxlo-9 
4 lOxlo-9 
4 lOxlo-9 
6 ·3oxio-9 
6 3ox10-9 
MAX. 
RESP. PAx 
(mm) 
145 8.50 
145 8.50 
138 8.00 
138 8.00 
137 7.50 
137 7.50 
Ao = The molar dose of the agonist to produce a 50% response. 
pD2 = The negative (-) log of the dose necessary to produce a 50% response. 
B. lo-q = The molar concentration of the antagonist. 
AB 
7.4xlo-5 
6.2x10-5 
1. 7xio-6 
2.2xio-6 4.3xlo-~ 
2.9xlo-
p~ = The negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
pAx = (q - log B). 
pA2 
8.12 
7.99 
8.41 
8.47 
8.34 
8.24 
AB = The molar dose of the agonist which produces a 50% response in the presence of the antagonist. 
pA2 = The negative (-) log of the molar concentration of antagonist which causes a shift of a factor 2; 
pA2 = p~ + log(x-1); x = Ao/AB. 
Pyri. = Tripelennamine hydrochloride. 
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EXPERIMENT NO. 
Phen. I I 1 
3 
3 
.5 
.5 
7 
Phen. TI I 1 
3 
3 
.5 
.5 
7 
TABLE 6 
PHENIRAMINE MALEATE ANTAGONISM TO HISTAMINE-INDUCED CONTRACTIONS 
OF ISOLATED GUINEA PIG ILEUM 
RESPONSE 'ID AGONIST RESPONSE 'ID AGONIST PLUS ANTAGONIST 
MAX. 
RESP. 
(mm) 
110 
109 
109 
109 
109 
109 
132 
136 
136 
13.5 
13.5 
137 
Ao 
6.7xlo-~ 
7.6xio-5 7.6xio-5 8.9x10-.5 
8.9xl0-.5 
6.3x10-
4.8x10-.5 
.5.6x10-g 
.5.6xio-
.5.4x10-.5 
.5.4x10-.5 
3.8xio-.5 
pD2 NO. 
.5.82 2 
.5. 88 2 
.5. 88 4 
.5. 9.5 4 
.5. 9.5 6 
.5.80 6 
.5. 68 2 
.5. 7.5 2 
.5. 7.5 4 
.5.73 4 
.5.73 6 
.5 • .58 6 
B. 10-q 
lxlo-7 
lxlo-7 
3xio-7 
3xlo:~ 
lOxlO 
lOxlo-7 
lxio-7 
lxio-7 
3xio-7 
3x10-7 
lOxlo-7 
lOxlo-7 
MAX. 
RESP. P~ 
(mm) 
111 7.00 
111 7.00 
112 6 • .50 
112 6 . .50 
113 6.oo 
113 '6.oo 
13.5 7,00 
13.5 7.00 
140 6 • .50 
140 6 • .50 
139 6.oo 
139 6.oo 
AB 
1. .5x10-~ 
2.lxlO-
3.6x10-~ 
.5.lx10-
1. 2x10-~ 
.5.9xlo-
_5.3x10-~ 
l.J.+x10-6 
2.8x10-6 2.6x10-6 7.ox10-
3._5x10-6 
pA2 
7.12 
7.23 
7.08 
7,17 
7.08 
6.92 
7.06 
7.18 
7.10 
7.08 
7,08 
6.92 
.i::--
-.J 
TABLE 6 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMENT NO. 
Phen. III I 1 
3 
3 
.5 
.5 
7 
MAX. 
RESP. 
(mm) 
1)6 
1.57 
1.57 
161 
161 
1.5.5 
A 
0 
.5.4xio-.5 
.5 6x10-.5 
• .5 ).6x10-5 ).3xlo-5 ).3xio-5 4.8x10-
pD2 
).73 
.5.7.5 
s. 7.5 
s. 72 
.5. 72 
).68 
NO. = The number of the curve being measured. 
NO. B. 10-q 
2 lxlo-7 
2 lxio-7 
4 3xio-7 
4 3xlo-7 
6 ·lOxlo-7 
6 lOxlo-7 
MAX. 
RESP. P~ 
(mm) 
1.58 7.00 
1.58 7.00 
1.58 6.)0 
1.58 6.)0 
1.58 6.oo 
1.58 6.oo 
Ao = The molar dose of the agonist to produce a.50% ,response. 
pD2 = The negative (-) log of the dose necessary to produce a .50% response. 
B. lo-q = The molar concentration of the antagonist. 
AB 
l.8x10-6 
2.ix10-6 
2.sxio-6 2.2xio-~ 
s.sx10-6 
4,7xio-
p.A_x = The negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
PAx = (q - log B). 
pA2 
7.38 
7.41 
7,04 
7.00 
6.97 
6.94 
AB = The molar dose of the agonist which produces a .50% response in the presence of the antagonist. 
pA2 = The negative (-) log of the molar concentration of antagonist which causes a shift of a factor 2; 
pA2 = pAx + log(x-1); x =Ao/AB. 
Phen. = Pheniramine maleate. 
-·~y'l\ktt~~ 
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TABLE 7 
MOR - TMPBZ ANTAGONISM TO HISTAMINE-INDUCED CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
EXPERIMENT 
Mor. I I 
Mor. TI I 
RESPONSE 'IO AGONIST 
NO. 
7 
9 
9 11 _,,, 
9 
11 
11 
13 
MAX. 
RESP. 
(mm) 
132 
134 
) 134 
134 
121 
122 
122 
120 
Ao 
5.4xio-§ 
5.9xlo-
5 5.9xlo-5 5.0xlO-
4.2x10-~ 
4.2xlo-
5 4.2xl0-5 
3.4x10-
pD2 
5,73 
5. 77 
5. 77 
5,70 
5.62 
5.62 
5.62 
5,53 
NO. 
8 
8 
10 
10 
10 
10 
12 
12 
RESPONSE TO AGONIST PLUS ANTAGONIST 
B. 10-q 
lxlo-t 
lxlO-
3xio-4 
3xlo-4 
lxlo-t 
lxlO-
3x10-t 
3xio-
MAX. 
RESP. 
(mm) 
132 
132 
130 
130 
115 
115 
114 
114 
pA 
x 
4.00 
4.00 
3,50 
3,50 
4.00 
4.00 
3.50 
3,50 
AB 
9.4x10-5 
6.Bxlo-5 
6.ox10-§ 
4.ox10-
pA2 
3,27 
3.05 
3.12 
2. 72 
~ 
'O 
TABLE 7 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMENT 
Mor. ill 
NO. 
1 
3 
3 
s 
MAX. 
RESP. 
(mm) 
124 
137 
137 
13S 
Ao 
3.8x10-S 
3.6x10-S 
3.6x10-S 
3.ox10-S 
pD2 
s.ss 
s.ss 
s.ss 
S.47 
NO. = The number of the curve being measured. 
NO. 
2 
2 
4 
4 
B. 10-q 
lx10-4 
lxlo-4 
3xio-4 
3xio-4 
MAX. 
RESP. 
(mm) 
133 
133 
131 
131 
Ao = The molar dose of the agonist to produce a SO% response. 
pD2 = The negative (-) log of the dose necessary to produse a SO% response. 
B. lo-q = the molar concentration of the antagonist. 
pA 
x 
4.00 
4.00 
3.so 
3.So 
AB pA2 
pA_x = The negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
pA_x = (q - log B). 
~ = The molar dose of the agonist which produces a SO% response in the presence of the antagonist. 
pft2 = The negative (-) log of the molar concentration of antagonist which causes a shift of a factor 2; 
pA2 = pA_x + log(x-1); x=A0 /AB. Mor. = Mor - TMPBZ. 
\J1 
0 
EXPERIMENT 
TMTI I 
TMT TI I 
TABLE 8 
TMT ANTAGONISM TO HISTAMINE-INDUCED CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
NO. 
1 
3 
3 
5 
1 
3 
3 
5 
RESPONSE TO AGONIST 
MAX. 
RESP. 
(mm) 
114 
118 
118 
121 
130 
125 
125 
130 
A 
0 
3.4x10-~ 
4.2x10-
5 4. 2xl0-
5 4.7x10-
5.ox10-~ 
5.ox10-
5.oxio-~ 
5.3x10-
pD2 
5.53 
5.62 
5.62 
5.67 
5.70 
5.70 
5.70 
5. 72 
NO. 
2 
2 
4 
4 
2 
2 
4 
4 
RESPONSE TO AGONIST PLUS ANTAGONIST 
B. 10-q 
lx10-t 
lxlO-
3xlo-t 
3xio-
lx10-t 
lxlo-
3xlo-4 
3x10-4 
MAX. 
RESP. 
(mm) 
117 
117 
122 
122 
129 
129 
122 
122 
pA 
x 
4.00 
4.00 
3.50 
3.50 
4.00 
4.00 
3.50 
3.50 
AB 
4.8x10-~ 
7.lxlo-
5 9.2xlo-
5 l.2xl0-
5.0x10-5 
5.oxio-5 
6.ox10-5 
6.ox10-5 
pA2 
3.55 
3.81 
3.41 
3.32 
2.59 
2.59 
2. 72 
2.83 
~ 
TABLE 8 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMENT 
TMT IIT 
NO. 
2 
4 
4 
6 
MAX. 
RESP. 
(mm) 
143 
144 
144 
144 
Ao 
4.7xlo-5 
5.0xlo-5 
5.0xlo-5 
5.6xio-5 
pD2 
5.67 
5.70 
5.70 
5, 75 
NO. = The number of the curve being measured. 
NO. 
3 
3 
5 
5 
B. 10-q 
lxlo-4 
lxlo-4 
3xio-4 
3xlo-4 
MAX. 
RESP. 
(mm) 
143 
143 
143 
143 
A0 = The molar dose of the agonist to produce a 50% respons e. 
pD2 = The negative (-) log of the dose necessary to produce a 50% response. 
B. lo-q = The molar concentration of the antagonist. 
p~ 
4.00 
4.00 
3,50 
3.50 
AB 
5.5xio-5 
8.5xio-5 
i.1xio- 6 
pAx = The negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
pAx = (q - log B). 
pA2 
2.90 
3,35 
3,41 
A = The molar dose of the agonist which produces a 50% response in the presence of th e antagonist. P~2 = The negative (-) log of the molar concentration of antagonist which causes a shift of a factor 2; 
pA2 = PA:x + log(x-1); x = Ao/AB. 
\ 
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TABLE 9 
PYL - TMPBZ ANTAGONISM TO HISTAMINE-INDUCED CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
RESPONSE TO AGONIST 
EXPERIMENT NO. 
Pyl-TMPBZ I I 1 
3 
3 
5 
5 
7 
Pyl-TMPBZ TII 5 
7 
7 
9 
:i.HS;·"··"tfifr?'71Y'i~~,. ,~~lke:f°~6..;\~s~'.""""bl;W;1 •. ,.1 
MAX. 
RESP. 
(mm) 
128 
130 
130 
124 
124 
129 
119 
123 
123 
121 
Ao 
5.ox10-~ 
5.6xio-
5 5.6xlo-
5 4.3xlo-
5 4.3x10-
5 5.4x10-
4.5xl0-~ 
4.8xlo-
5 4.8xio-
5 4. 2xlo-
pD2 
5.70 
5.75 
5.75 
5. 63 
5.63 
5.73 
5.65 
5. 68 
5.68 
).62 
NO. 
2 
2 
4 
4 
6 
6 
6 
6 
8 
8 
RESPONSE TO AGONIST PLUS ANTAGONIST 
B. 10-q 
lOxlo-5 
lOxlo-5 3ox10-~ 
30x10-
3xlo-~ 
3xio-
lOxlO-~ 
lOxlo-
5 30xl0-
30xlo-5 
MAX. 
RESP. P.Ax 
(mm) 
127 4.00 
127 4.00 
125 3,50 
125 3.50 
127 4.50 
127 4.50 
118 4.00 
118 4.00 
113 3.50 
113 3.50 
AB 
6.5x10-~ 
8.4x10-6 
l.6xl0-
8.6x10-5 
4.5xl0-~ 
5.3x10-
5 8.2x10-
5 5.9xlo-
pA2 
3.49 
3,67 
3. 71 
3.50 
2.59 
3.04 
3.31 
3.12 
\Jl. 
w 
TABLE 9 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMENT 
Pyl-TMPBZ ill 
NO. 
5 
7 
7 
9 
MAX. 
RESP. 
(mm) 
135 
131 
131 
134 
Ao 
3.ox10-5 
2.5x10-5 
2.5x10- 5 
3.2xio-5 
pD2 
5,47 
5.40 
5,40 
5.50 
NO. = The number of the curve being measured. 
NO. 
6 
6 
8 
8 
B. 10-q 
lOxlo-5 
lOxlo-5 
30xlo-5 
30xlo-5 
MAX. 
RESP. 
(mm) 
133 
133 
123 
123 
A0 = The molar dose of the agonist to produce a 50% r esponse. 
pD2 = The negative (-) log of the dose necessary to produce a 50% response. 
B. 10-q = The molar concentration of the antagonist. 
p~ 
4.00 
4.00 
3,50 
3.50 
AB 
3.9xlo-5 
2.Bxlo-5 
3,3x10-5 
5.ix10-5 
pAx = The negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
pAx = (q - log B). 
pA2 
3.41 
2.90 
2.91 
3.27 
A = The molar dose of the agonist which produces a 50% response in the presence of the antagonist. P~2 = The negative (-) log of the molar concentration of antagonist which causes a shift of a factor 2; 
pA2 = pAx + log(x-1); x = A0 /AB• 
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EXPERIMENT 
TMBD I I 
TMBD II I 
TABLE 10 
TMBD ANTAGONISM TO HISTAMINE-INDUCED CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
NO. 
2 
4 
4 
6 
6 
8 
1 
3 
3 
s 
5 
7 
RESPONSE TO AGONIST 
MAX. 
RESP. 
(mm) 
108 
107 
107 
108 
108 
108 
132 
132 
132 
134 
134 
128 
Ao 
4 -s 7. xlO S 
7.9x1o=s 
7.9xl0 s 
7.6x10-
5 7.6x10-6 1. 2xl0-
S.9xlo-~ 
6.7xio-
5 6.7xio-
6.8x10-~ 
6.8x10-
5 6.7xlo-
pD2 
S.87 
S.90 
S.90 
S.88 
S.88 
6.07 
s. 77 
5.82 
S.82 
S.83 
S.83 
5.82 
NO. 
3 
3 
s 
s 
7 
7 
2 
2 
4 
4 
6 
6 
RESPONSE TO AGONIST PLUS ANTAGONIST 
B. 10-q 
3xl0-~ 
3xlo-lOxlo-~ 
10x10-
5 30xlo-
3ox10-S 
3xlo-~ 
3xlo-
lOxlo-S lOxlO-~ 
30x10-
5 3oxio-
MAX. 
RESP. pAx 
(mm) 
107 4.So 
107 4.So 
103 4.00 
103 4.00 
102 3.So 
102 3.50 
129 4.So 
129 4.50 
128 4.00 
128 4.00 
133 3.50 
133 3.So 
A B 
8.9xl0=~ 
1.0xlO b 
l.Sx10-
i.i+x10-6 
4.3xlo-6 
l.Oxlo-7 
6.Sx10-~ 
8.7x10-6 l.9xlo-6 l.4xlo- 6 3.7x10-6 3.Sxlo-
~~l¢iir•' t¥t# Hitft · ~"ff-¥?E' '\;itjii.1,:e~ .. ,,..,,& ';.Q· -,.·1&*"··. ··-'"'tdir ·tsn~wsri&MPf!Nic,w . _ .etMJi;,fr· .. - ~ac· , nt q;- -; 1ttf 5, ~c·.·y .,. 
pA2 
3. 72 
3. 91 
3.93 
3.89 
4.17 
4.38 
3.54 
3. 91 
4.26 
4.29 
4,14 
4.12 
Vl. 
Vl. 
TABLE 10 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMENT NO. 
TMBD IIT I 1 
3 
3 
5 
5 
7 
MAX. 
RESP. 
(mm) 
108 
112 
112 
111 
111 
109 
Ao pD2 
7. 9xl0-~ 5.90 
6.3x10-
5 5.80 6.3x10-
5 
5.80 
7.9xlo-
5 
5.90 
7.9xlo-
5 
5.90 
6. 8x10- 5.83 
NO. = The number of the curve being measured. 
NO. B. 10-q 
2 3xlo-; 
2 3xlo-
4 lOxlO-~ 
4 lOxlo-5 6 30xlo-
5 6 30xl0-
MAX. 
RESP. PiSc 
(mm) 
110 4.50 
110 4.50 
110 4.00 
110 4.00 
100 3.50 
100 3.50 
A0 = The molar dose of the agonist to produce a 50% re sponse. 
pD2 = The negative (-) log of the dose necessary to produce a 50% response. B. lo-q = The molar concentration of the antagonist. 
A B 
i.i+x10-~ 
8.8x10-
6 1. 6x10-6 2.6x10- 6 7,3x10-
6 5.8x10-
pAx = The negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
pAx = (q - log B). 
pA2 
4.39 
4.12 
4.21 
4.36 
4.42 
4.34 
AB = The molar dose of the agonist which produces a 50% response in the presence of the antagonist. 
pA2 = The negative (-) log of the molar concentration of antagonist which causes a shift of a factor 2; pA2 = PAx + log(x-1); x = A0 /AB. 
V1. 
°' 
TABLE 11 
DMA - TMPP ANTAGONISM TOI HISTAMINE-INDUCED CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
EXPERIMENT NO. 
Dma-TMPP I I 7 
9 
9 
11 
Dma-TMPP JI I 1 
3 
3 
5 
RESPONSE TO AGONIST 
MAX. 
RESP. 
(mm) 
129 
131 
131 
127 
115 
118 
118 
119 
Ao 
5.6xio-~ 
7.9xlo-
5 7.9xlo-
5 5.3xl0-
4 oxio-5 
. 5 4.5x10-5 4.5xlo-
5 4.2xl0-
pD2 
5,75 
5.90 
5,90 
5. 72 
5.60 
5.65 
5.65 
5.62 
NO. 
8 
8 
10 
10 
2 
2 
4 
4 
RESPONSE TO AGONIST PLUS ANTAGONIST 
B. 10-q 
lxlo-t 
lxio-
3xlo-t 
3xlo-
lxlo-4 
lxlo-t 
3xlo-
4 3xl0-
MAX. 
RESP. 
(mm) 
127 
127 
117 
117 
115 
115 
98 
98 
pA 
x 
4.00 
4,00 
3.50 
3,50 
4.00 
4.00 
3.50 
3.50 
AB 
3.2~0- 6 
L4x10-6 
8.6~10-~ 
7,6x10-
pA2 
3,97 
3, 71 
3,46 
3.39 
\JI. 
--J 
·~ 
TABLE 11 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMENT 
Dma- TMPP ill 
NO. 
1 
3 
3 
5 
MAX. 
RESP. 
(mm) 
132 
129 
129 
131 
Ao 
3.4xl0-5 
3.8x10-5 
3.8x10-5 
3.ox10-5 
pD2 
5,53 
5, 58 
5.58 
5,47 
NO. = The number of the curve being measured. 
NO. 
2 
2 
4 
4 
B. 10-q 
lx10-4 
lxlo-4 
3x10-4 
3xio-4 
MAX. 
RESP. 
(mm) 
135 
135 
131 
131 
A = The molar dose of the agonist to produce a 50% response. 
pB2 = The negative (-) log of the dose necessary to produce a 50% response. 
B. 10-q = The molar concentration of the antagonist. 
pAX 
4.00 
4.00 
3,50 
3,50 
AB 
-
7.2x10-5 
4. 2xlo-5 
p~ = The negative (- ) log of the molar dose of the antagonist needed to cause a shift x; 
pAx = (q - log B). 
pA2 
3,43 
3.12 
A = The molar dose of the agonist which produces a 50% response in the presence of the antagonist. 
P£2 ~ The negative (-) log of the molar concentration of antagonist which causes a shift of a factor 2; 
pA2 = pAx + log(x-1); x = A0 /AB. 
\51. 
OJ 
FIGURE 8 
CUMULATIVE DOSE-RESPONSE CURVES OF HISTAMINE 
ON THE GUINEA PIG ILEUM IN THE PRESENCE 
AND ABSENCE OF PAPAVERINE 
Note that the maximum response of histamine diminishes as the 
concentration of papaverine (a known non-competitive antagonist) 
is increased. 
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FIGURE 9 
CUMULATIVE DOSE-RESPONSE CURVES AS CALCULATED FROM FIGURE 8 
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I.OG DOSE OF HISTAMINE IN MOLES 
1he affinity of papaverine (a non-competitive antagonist) for 
the receptor site can be calculated as a pD 12 value from the 
reduction in the maximum-induced histamine response. 
TABLE 12 
PAPAVERINE HYDROCHLORIDE ANTAGONISM TO HISTAMINE-INDUCED 
CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERD1ENT NO. 
PAPA VERINE I 2 
4 
4 
6 
6 
8 
8 
10 
MAX. 
RESP. 
(mm) 
141 
144 
144 
144 
144 
149 
149 
143 
A 
0 pD2 
3.4xlo-~ 5.53 
3.7xio-5 5.57 
3.7xio-
5 
5.57 
2.7xio-5 5.43 2.7xlO- .5.43 3.1xio-~ s.s1 
3.7xio- s • .57 
3.7xio-S S • .57 
NO. = 'Ille number of the curve being measured. 
NO. B. 10..;.P 
3 lOxlo-6 
3 lOxl0-6 
5 3xio-6 
5 3xio-6 
7 3oxio-6 
7 3oxio-6 
9 2oxio-6 
9 2oxio-6 
MAX. 
RESP. 
(mm) 
58 
58 
133 
133 
10 
10 
34 
34 
Ao = The molar concentration of agonist to produce a .50% response. 
pD2 = 'Ille negative (-) log of the dose necessary to produce a .50% response. 
B. 110-P =The molar concentration of the antagonist. 
I 
pDx 
5.00 
5.00 
5.50 
5.50 
4.50 
4.So 
4.70 
4. 70 
% 
41 
40 
91 
91 
7 
7 
23 
24 
' pD 2 
s.16 
s.18 
s.23 
s.20 
pD x = The negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
pD ~ = (p - log B) • 
% = The maximum effect of the agonist in the presence of the antagonist is expressed as a percentage 
of the maximum effect of the agonist alone; % = 100/x. 
pD 12 = 'Ille negative log of the molar concentration which causes a 50% depression; pD
12 = pD~ + log(x-1). 
g;-
FIGURE 10 
CUMULATIVE DOSE-RESPONSE CURVES OF HISTAMINE 
ON THE GUINEA PIG ILEUM IN THE PRESENCE 
AND ABSENCE OF DE-TMPBZ 
Note that the maximum response of histamine diminishes as the 
concentration of De-TMPBZ is increased. 
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FIGURE 11 
CUMULATIVE DOSE-RESPONSE CURVES AS CALCULATED FROM FIGURE 10 
DE-TMPBZ JI 
0 
3 
10 
30 
LOG DOSE OF HISTAMINE IN MOLES 
'Ihe affinity of De-TMPBZ for the receptor site can be calcu-
lated as a pD 12. value from the reduction in the maximum 
induced histanune response. 
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TABLE 13 
DE - TMPBZ ANTAGONISM TO HISTAMINE-INDUCED CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
EXPERIMENT NO. 
De-TMPBZ I I 1 
3 
3 
5 
5 
7 
De-TMPBZ TI I 1 
3 
3 
5 
5 
7 
RESPONSE TO AGONIST 
MAX. 
RESP. 
, (mm) 
117 
115 
115 
114 
114 
110 
121 
131 
131 
134 
134 
136 
A 
0 
5.9xio-~ 
6.3xio-
6.3xio-~ 
6.8xio-5 6.8x10-5 
8.9xl0-
pD2 
5.77 
5.80 
5.80 
5.83 
5.83 
5.95 
5.oxio-5 5.70 
5.6xio-g 5.75 
5.6xio- 5.75 6.7xio-~ 5.82 
6.7xio- 5.82 
6.oxio-5 5.78 
NO. 
2 
2 
4 
4 
6 
6 
2 
2 
4 
4 
6 
6 
RESPONSE TO AGONIST PLUS ANTAGONIST 
B. lo-P 
3xio-5 
3xio-5 
lOxlo-5 
loxio-5 
3oxio-5 
30x10-5 
3xio-5 
3xio-5 
lOxlo-5 
lOxlo-5 
3oxio-5 
3oxio-5 
(' 
MAX. 
RESP. 
(mm) 
115 
115 
106 
106 
84 
84 
131 
131 
113 
113 
92 
92 
I pDx % 
4.50 98 
4.50 100 
4.00 92 
4.00 93 
3.50 74 
3.50 76 
4.50 103 
4.50 100 
4.00 86 
4.00 84 
3.50 69 
3.50 68 
I pD2 
3.04 
3.01 
3.20 
3.23 
3.15 
3.17 
~ 
TABLE 13 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMENT NO. 
De-TMPBZ III I 1 
3 
3 
s 
s 
7 
MAX. 
RESP. 
(mm) 
1S4 
1S4 
1S4 
148 
148 
154 
Ao pD2 
S.9xlo-~ S.77 
6.8xlo- S.83 
6.8xlo-~ S.83 
6.3xlo-s s.80 
6.3xlo-s s.80 
S.9xlo- S.77 
NO. = 'Ihe number of the curve being measured. 
MAX. 
I RESP. pD 
(mm) x 
B. lo-P NO. 
2 3xlo-S 1S3 4.so 
2 3xlo-S 1S3 4.So 
4 lOxlo-S 144 4.00 
4 lOxlo-S 144 4.00 
6 30xlo-S 114 3.so 
6 30xlo-5 114 3.So 
A = 'Ihe molar concentration of agonist to produce a SO% response. 
PB2 = The negative (-) log of the dose necessary to produce a 50% response. 
B. lo-P = The molar concentration of the antagonist. 
pD'x = 'Ihe negative (-) log of the molar dose of the antagonist needed to cause a shift x; 
pD~ = (p - log B). . 
% 
99 
99 
93 
97 
77 
74 
I 
pD2 
2.98 
3.04 
% = The maximum effect of the agonist in the presence of the antagonist is expressed as a percentage 
1 of the maximum effect of the agonist alone; % = 100/x. 1 pD 2 = 'Ihe negative log of the molar concentration which causes a SO% depression; pD 2 = pD~ + log (x-1). 
( °' VI. 
EXPERIMENT 
TMPBZ I 
TMPBZ JI 
TABLE 14 
TMPBZ ANTAGONISM TO HISTAMINE-INDUCED CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
NO. 
I 11 
13 
13 
15 
15 
17 
I 1 
3 
3 
5 
5 
7 
RESPONSE TO AGONIST 
MAX. 
RESP. 
(mm) 
134 
130 
130 
131 
131 
126 
129 
122 
122 
120 
120 
116 
~ pD2 
5.3xio-~ 5.72 
5.9xlo-5 5.77 5.9xlo-5 5.77 5.6xio-
5 
5.75 
5.6xio- 5.75 
5.6xio-5 5.75 
2.8xio-~ 5.45 
3.4xlo-5 5.53 3.4xlo-5 5.53 4.oxio-5 5.60 4.oxio-5 5.6o 3.oxio- 5.48 
NO. 
12 
12 
14 
14 
16 
16 
2 
2 
4 
4 
6 
6 
RESPONSE TO AGONIST PLUS ANTAGONIST 
B. 10-P 
lOxlo-5 
lOxlo-5 
3xio-5 
3xl0-5 
3oxio-5 
3oxio-5 
c 
lOxlo-5 
lOxlo-5 
3xio-5 
3xio-5 
3oxio-5 
30x10-5 
MAX. 
RESP. 
(mm) 
79 
79 
108 
108 
44 
44 
62 
62 
82 
82 
11 
11 
I 
pDX 
4.00 
4.00 
4.50 
4.50 
3.50 
3. 50 
4.00 
4.00 
4.50 
4.50 
3.50 
3.50 
% 
59 
61 
83 
82 
34 
35 
48 
51 
67 
68 
9 
9 
I , 
pD2 
3.85 
3.81 
3.80 
3.84 
3.79 
3.77 
4.03 . 
3.98 
4.19 
4.17 
~ 
TABLE 14 - Continued 
RESPONSE TO AGONIST RESPONSE TO AGONIST PLUS ANTAGONIST 
EXPERIMEN1' NO. 
TMPBZ ill I 7 
9 
9 
11 
11 
13 
MAX. 
RESP. 
(mm) 
137 
132 
132 
133 
133 
129 
Ao pD2 
4.7xio-~ S.67 
4.8xio-
5 
S.68 
4.8xio-
5 
S.68 
6.3xio-
5 
s.so 
6.3xio-
5 
S.80 
s.0x10- 5.70 
ID. = The number of the curve being measured. 
NO. B. lo-P 
8 3xio-S 
8 3xio-S 
10 lOxlo-5 
10 lOxlO:g 
12 30xl0 
12 3oxio-S 
A = The molar concentration of agonist to produce a 50% response. 
MAX. 
RESP. pD I 
(mm) x 
112 4.So 
112 4.So 
76 4.00 
76 4.00 
26 3.50 
26 3.So 
(., 
pB2 = The negative (-) log of the dose necessary to produce a 50% response. B. lo-P = The molar concentration of the antagonist. 
pD~= 'Illr negative(-) log of the molar dose of the antagonist needed to cause a shift x; 
pD x = (p - log B) • 
% 
82 
85 
58 
57 
20 
20 
I 
pD 2 
3.84 
3.73 
3.86 
3.88 
3.90 
3.90 
% = The maximum effect of the agonist in the presence of the antagonist is expressed as a percentage 
of the maximum effect of the agonist alone; % = 100/x. 
1 pD'2 = The negative log of the molar concentration which causes a 50% depression; pD
1
2 = pD x + log(x-1). 
) 
-;;:y~:~:~- ·~ 1~ .'.: 11&1i1..1L·::$;1¥:$\£)ir:·"':'.~-;·:;,,~1.~ 
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TABLE 15 
A SUMMARY OF COMPETITIVE DRUG ANTAGONISM OF HISTAMINE-INDUCED 
CONTRACTIONS OF ISOLATED GUINEA PIG ILEUM 
COMPOUND MEAN E!2 ± S.D. 
Tripelennamine Hydrochloride 8.40 0.18 
Diphenhydramine Hydrochloride 7.75 0.16 
Pheniramine Maleate 7.10 0.14 
2-(3,4,5-trimethoxybenzhydryloxy)-N,N-dimethyl-
ethylamine Succinate (TMBD) 4.12 0.25 
-(l-Piperidino)-N-(2-pyridyl)-N-(3,4,5-trimethoxy-
benzyl) ethylamine Dicyclamate (Pip-TMPBZ) 3.54 0.35 
-Dimethylamino-3,4,5-trimethoxypropiophenone 
Hydrochloride (Dma-TMPP) 3.51 0.29 . 
-(l-Pyrrolidino)-N-(2-pyridyl)-N-(3,4,5-trimethoxy-
benzyl) ethylamine Dicyclamate (Pyl-TMPBZ) 3.24 0.35 
l-(2-pyridyl)-1-(3,4,5-trimethoxyphenyl)-3-dimethyl-
aminopropane Cyclamate (TMT) 3.13 0.42 
-(4-Morpholino)-N-(2-pyridyl)-N-(3,4,5-trimethoxy~ 
benzyl) ethylamine Dicyclamate (Mor-TMPBZ) 3.04 0.23 
• 
i . 
I 
I 
i 
TABLE 16 
A SUMMARY OF NON-COMPETITIVE DRUG ANTAGONISM OF HISTAMINE-INDUCED 
CONTRACTIONS OF ISOLA.TED GUINEA PIG ILEUM 
COMPOUND 
Papaverine Hydrochloride 
N,N,-Dimethyl-N'-(2-pyridyl)-N'-(3,4,5-trimethoxy-
benzyl) ethylenediamine Disuccinate (TMPBZ) 
N,N,-Diethyl-N '. -(2-pyridyl)-N'-(3,4,5-trimethoxy-
benzyl) ethylenediamine Dicyclamate (DE-TMPBZ) 
MEAN pD' ± S D ----~2 .• 
s.19 
3.90 0.13 
3.10 0.09 
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TABLE 17 
EFFECT OF DIPHENHYDR.AMINE HYDROCHIDRIDE ON THE SYSTOLIC Bl(X)D PRESSURE 
OF MALE ALBINO RATS 
DOSE DOSE NORMAL DEPRESSOR RESPONSE PRESSOR RESPONSE 
fules/Kg Mg/Kg BLOOD PRESSURE DURATION % (mmHg) (min:sec) 
DURATION % 
(min:sec) 
i.o x lo-3 0.29 94 3110" 11 
3.0 x lo-3 o.87 114 .5'00 11 22 
i.o x 10-2 2.92 90 1'00 11 79 11 106 11 24 
3.0 x lo-2 
I 
8.7.5 84 3'10" 63 41'10 11 .51 
. -
% = '!he maximum systolic pressor or maximum depressor response expressed as a 
percent of the normal blood pressure. 
-.J 
0 
DOSE 
Moles/Kg 
5.o x lo-2 
i.o x lo-1 
2.0 x lo-1 
TABLE 18 
EFFECT OF TMBD ON THE SYSTOLIC BLOOD PRESSURE OF MALE ALBINO RATS 
DOSE NORMAL 
Mg/Kg BLOOD PRESSURE 
(nunHg) 
23.20 100 
46.40 86 
98. 70 74 
DEPRESSOR RESPONSE 
DURATION % (min: sec) 
2 1 20 11 20 
2 110 11 27 
2100" 66 
PRESSOR RESPONSE 
DURATION 
(min: sec) % 
4' 50" 2 
12' 50" 22 
% = '!he maximum systolic pressor or maximum systolic depressor response expressed as a 
percent of the normal blood pressure. 
j 
-.J 
b-1 
TABLE 19 
EFFF.CT OF PHENIRAMINE MALEATE ON THE SYSTOLIC BLOOD PRESSURE OF MALE 
ALBINO RATS 
DOSE DOSE NORMAL DEPRESSOR RESPONSE PRESSOR RESPONSE 
Moles/Kg Mg/Kg BLOOD PRESSURE DURATION % DURATION % (mmHg) (rriin: sec) (min:sec) 
3.0 x lo-3 1.07 106 21 20 11 13 29'30" 9 
i.o x 10-2 3.56 99 3'30" 15 35' 50" 19 
3.0 x lo-2 10. 70 94 10'35" 15 20 110 11 9 
i.o x l.o-1 35.60 76 20 100 11 18 35'30" 30 
% = 'Ihe maximum systolic presser or maximum systolic depressor response expressed as a 
percent of the normal blood pressure. 
-.J 
I\) 
TABLE 20 
EFFECT OF DMA - TMPP ON THE SYSTOLIC BLOOD PRESSURE 
OF MALE ALBINO RATS 
DOSE DOSE NORMAL DEPRESSOR RESPONSE 
Moles/Kg Mg/Kg BLOOD PRESSURE DURATION 
(mrnHg) (min:sec) 
2.5 x 10-2 7.60 94 10'05" 
5.0 x 10-2 15.20 84 8 130" 
i.o x lo-1 30.40 112 14'10 11 
1.5 x 10-1 45.60 96 27'25" 
% = 'Ihe maximum systolic depressor response expressed as a 
percent of the normal blood pressure. 
% 
32 
31 
43 
42 
) 
-
-.J 
\....! 
- . ~~}j_ .... .-"!.,• 
, TABLE 21 
EFFECT OF TMT ON THE SYSTOLIC BLOOD PRESSURE 
OF MALE ALBINO RATS 
DOSE DOSE NORMAL PRESSOR RESPONSE 
Moles/Kg Mg/Kg BLOOD PRESSURE DURATION % (rmnHg) (min:sec) 
2.5 x lo-2 12.7 104 20 100 11 22 
5.0 x 10~2 25.5 98 32'50" 31 
i.o x lo-1 51.0 104 6115" 35 
1.5 x lo-1 76.4 
I 
106 30 1 20 11 47 
% = 'Ihe maximum systolic pressor response expressed as a percent 
of the normal blood pressure. 
~'·:.,::;: 
-J 
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TABLE 22 
EFFECT OF TRIPELENNAMINE HYDROCHLORIDE ON THE SYSTOLIC BLOOD PRESSURE 
OF MALE ALBINO RATS 
DOSE DOSE NORMAL DEPRESSOR RESPONSE PRESSOR RESPONSE 
Moles/Kg Mg/Kg BLOOD PRESSURE DURATION % DURATION (nunHg) (min:sec) (min:sec) 
i.o x lo-2 2.92 83 1'40" 54 7'10" 
2.0 x lo-2 5.84 80 3'15" 64 21'30" 
3.0 x 10-2 8.76 97 12'50" 45 31'00" 
4.o x lo-2 
I 
11.68 90 21 20 11 72 42'10" 
% = The maximum systolic pressor or maximum depressor response expressed as a 
percent of the normal blood pressure. 
% 
6 
20 
28 
22 
-.J 
\J"I. 
TABLE 23 
EFFF.GT OF TMPBZ ON THE SYSTOLIC BLOOD PRESSURE 
OF MALE ALBINO RATS 
DOSE DOSE NORMAL DEPRESSOR RESPONSE 
Moles/Kg Mg/Kg BLOOD PRESSURE DURATION % (mmHg) (min:sec) 
i.o x lo-2 5.8 78 5'05" 23 
2.0 x lo-2 11.6 94 61 35" 36 
3.0 x lo-2 17.4 97 7'50" 51 
4.o x lo-2 23.3 108 10 1 20 11 55 
% = 'lhe maximum systolic depress;r response expressed as a percent 
of the normal blood pressure. 
-.J 
°' 
TABLE 24 
EFFECT OF DE - TMPBZ ON THE SYSTOLIC BIOOD PRESSURE 
OF MALE ALBINO RATS 
DOSE OOSE NORMAL DEPRESSOR RESPONSE 
Moles/Kg Mg/Kg BLOOD PRESSURE DURATION 
(mmHg) (min:sec) 
i.o x lo-2 7.3 105 21 20 11 
2.0 x 10-2 14.6 87 2'40" 
3.0 x lo-2 22.0 120 8 110 11 
4.0x lo-2 
I 
29.3 120 6 150" 
% = 'Ihe maximum systolic depressor response expressed as a 
percent of the normal blood pressure. 
% 
28 
43 
47 
18 
-.] 
-.] 
TABLE 25 
EFFECT OF PIP - TMPBZ ON THE SYSTOLIC BLCDD PRESSURE 
OF MALE ALBINO RATS 
DOSE DOSE NORMAL PRESSOR RESPONSE 
Moles/Kg Mg/Kg BLOOD PRESSURE DURATION 
(mmHg) (min: sec) 
2.0 x 10 -2 14.9 108 1 100 11 
3.0 x lo-2 22.3 88 2140" 
5.o x lo-2 37.2 104 61 35" 
i.o x lo-1 74-.4 88 23'04" 
% = 'Ihe maximum systolic pressor response expressed as a 
percent of the normal blood pressure. 
% 
6 
24 
15 
44 
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TABLE 26 
EFFECT OF PYL - TMPBZ ON THE SYSTOLIC BLOOD PRESSURE 
OF MALE ALBINO RATS 
DOSE DOSE NORMAL PRESSOR RESPONSE 
Moles/Kg Mg/Kg BLOOD PRESSURE DURATION 
(mmHg) (min: sec) 
5.0 x 10-2 36.5 122 0'50" 
7.5 x 10-2 54.8 74 23 100" 
l.o x lo-1 73.0 84 47'50" 
1.5 x lo-1 109.5 113 43'50" 
% = The maximum systolic presser response expressed as a 
percent of the normal blood pressure. 
% 
7 
53 
40 
31 
-.J 
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TABLE 27 
EFFECT OF MOR - TMPBZ ON THE SYSTOLIC BI.DOD PRESSURE · 
OF MALE ALBINO RATS 
DOSE DOSE NORMAL PRESSOR RESPONSE 
Moles/Kg Mg/Kg BLOOD PRESSURE DURATION 
(mmHg) (rnin:sec) 
5.o x lo-2 37.3 102 2140" 
7.5 x lo-2 56.o 115 7'15" 
i.o x io-1 74.6 108 5'50" 
1.5 x lo-1 111.9 77 24'00 11 
% = The maximum systolic pressor response expressed as a 
percent of the normal blood pressure. 
% 
29 
23 
22 
53 
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TABLE 28 
THE EFFF.CT OF DMA-TMPP AND PHENIRAMINE ON THE EXPLORATORY 
ACTIVITY OF MALE ALBINO MICE 
CAGE I CAGE I 
Time Vehicle-Treated Vehicle-Treated "t" Test 
Minutes (0.2 ml. water) (0.2 ml. water) Evaluation 
X ± S.D. C(%) X ± S.D. C(%) 
0-15 808 203 8:1 843 174 2Q.b N.S. 
0-30 1272 395 31.1 1330 498 37.4 N.S. 
CAGE II CAGE II 
Vehicle-Treated , Pheniramine-Treated 
(0.2 ml. water) ( 1xlo-r WKg.) 
X ± S.D. C(%) X ± S.D. C(%) 
0-15 12J9 43 3:4 1484 218 14.7 SIG. 
0-30 2004 188 9.2 2687 506 18.8 SIG. 
CAGE III CAGE III 
. 
Vehicle-Treated Dma-TMPP 1 -Treated (o. 2 ml. water) ( 1xlo-r WKg.) 
X ±.S.D. C(%) X ± S.D. C(%) 
0-15 13B°7 IB 11.9 1544 227 l4.7 N.S. 
0-30 2217 235 10.9 2495 636 25.5 N.S. 
CAGE IV CAGE IV 
Vehicle-Treated Dma-TMPP"-Treated 
(o. 2 ml. water) ( 2xio-1 WKg. ) 
X ± S.D. C(%) X ± S.D. C(%) 
0-15 13B°2 221 16.o 12B°l 152 11.9 N.S. 
0-30 2019 447 22.2 2157 256 12.l N.S. 
X ± S.D. = The mean counts generated per unit time ± the standard 
deviation. 
C = Coefficient of variation, S.D./X x 100%. 
Comparisons were evaluated by means of Student's "t" Test (Snedecor, 
1956), with SIG. = Significant (P.::=0.05) and N.S. = Not Significant 
(Ps:0.05). 
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TABLE 29 
'IlIE EFFECT OF MOR-TMPBZ AND TRIPELENNAMINE ON THE EXPIDRATORY 
ACTIVITY OF MALE ALBINO MICE 
CAGE I CAGE I 
Time 
Minutes 
Vehicle-Treated 
(0.2 ml. water) 
Vehicle-Treated 
(0.2 ml. water) 
"t" Test 
Evaluation 
0-15 
0-30 
0-15 
0-30 
0-15 
0-30 
0-15 
0-'30 
X ± S.D. 
808 203 
1272 395 
C(%) 
~ 
31.1 
CAGE II 
Vehicle-Treated 
(o. 2 ml. water) 
X + S.D. 
12J9- 43 
2004 188 
C(%) 
3.4 
9.2 
CAGE III 
Vehicle-Treated 
(o. 2 ml. water) 
X + S.D. 
138"7- m 
2217 235 
C(%) 
11.9 
10.9 
CAGE IV 
Vehicle-Treated , 
(0.2 ml. water) 
X ± S.D. 
138°3 221 
2019 447 
C(%) 
16.o 
22.2 
X ± S.D. 
923 289 
1581 647 
CAGE II 
C(%) 
31.4 
40.9 
Tri1elennamine-Treated 
7.6 x lo-2 M/Kg.) 
X ± S.D. 
1297 260 
2473 491 
C(%) 
20.0 
19.8 
CAGE III 
Mor-TMPBZ'-Treated 
(7.6 x l0-2 M/Kg.) 
X ± S.D. 
625 197 
811 184 
C(%) 
31. 7 
22.7 
CAGE IV 
Mor-TMPBZ"-Treated (1.$ x lo-1 M/Kg.) 
X ± S.D. 
394 90 
670 194 
C(%) 
22."8" 
28.9 
N.S. 
N.S. 
N.S. 
N.S. 
SIG. 
SIG. 
SIG. 
SIG. 
X ± S.D. = 'Ihe mean counts generated per unit time ± the standard 
deviation. 
C = Coefficient of variation, S.D./X x 100%. 
Comparisons were evaluated by means of Student's "t" Test (Snedecor, 
1956), with SIG. = Significant (P~0.05) and N.S. = Not Significant 
(P~0.05). 
0 
FIGURE 12 
COMPARISON OF C VALUES PER UNIT TIME GENERATED BY VEHICLE-TREATED 
MALE ALBINO MICE IN THE ACTOPHOTOMETER 
40 
30 
20 
10 
0-10 10-20 20-30 0-15 15-30 0-30 
UNIT TIME 
C = Coefficient of variation (S.D./X x 100%) 
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V. DISCUSSION 
A. ISOLATED TISSUE STUDY 
'Ihe cumulative dose-response technique of Van Rossum and Van Den 
Brink (1963) proved to be a valid method for measuring the histamine 
antagonizing ability of the parent compounds and their analogs. As 
expected, the parent compounds were shown to be highly effective 
competitive antagonists of histamine-induced smooth muscle contrac-
tions. 'lhe pA2 values in Table lS quantify this effectiveness and 
serve as convenient standards for evaluating the antihistamine 
properties of the trimethoxy analogs. 
'Ihe histamine-antagonizing abilities of the trimethoxy-substi-
tuted antihistamines were, in all cases, much weaker than the origi-
nal parent compound, (Tables lS and 16). All the analogs exhibited 
some competitive or non-competitive antagonism of histamine-induced 
smooth muscle spasms. De-TMPBZ and TMPBZ, which are analogs of 
tripelennamine, were shown to be non-competitive histamine antagonists. 
In terms of potency, De-TMPBZ and TMPBZ were about 10-100 times weaker 
than papaverine, which is a known non-competitive inhibitor of hista-
mine, (Table 16). 'Ihe remaining tripelennamine analogs were all com-
petitive inhibitors, as .was tripelennamine itself, and were approxi.-
mately 10,000-100,000 times weaker than their parent antihistamine, 
(Table 15). 
According to Van Rossum (1963), the difference in the type of 
inhibition shown by tripelennamine and the two non-competitive analogs, 
De-TMPBZ and TMPBZ, indicates a basic change in the activity of the 
experimental drugs from the parent compound. He stated that competitive 
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and non-competitive inhibitors elicit their different responses by 
means of independent receptor sites. 
It seems phat the changes in activity of the above tripelennamine 
analogs are dependent upon the presence of a 3,4,5-trimetho:xyphenyl 
substitution and the presence of either a terminal dimethyl or diethyl 
group. The necessity of both types of substitutions can be seen by 
examining the structural formulas of tripelennamine, Mor-TMPBZ, 
Pyl-TMPBZ, and Pip-TMPBZ, (Figure 1). These compounds are competitive 
histamine antagonists and have the same structural formula as De-TMPBZ 
and TMPBZ except that they lack either the trimetho:xy group or the 
terminal diethyl or dimethyl group. However, . the presence of these 
two chemical groups on an antihistamine drug does not necessarily 
mean that the compound will be a non...:competitive inhibitor. TMBD 
and TMT both have a trimetho:xy group and a terminal dimethyl group 
and are competitive antagonists of histamine. It appears that the 
receptor sites ·exhibit a high degree of specificity as TMT and TMPBZ, 
which have very similar chemical structures, are different types of 
antagonists. 
B. BI.DOD PRESSURE STUDY 
The results of the blood pressure study (Tables 17-27) show that 
the parent compounds and their trimetho:xy analogs did not have a 
significant effect upon the systolic blood pressure of male albino 
rats. 'Jhis is in agreement with the earlier works of La.Belle and 
Tislow (1955). Yonkman et al. (1946), and Loew et al. (1946), who 
reported that pheniramine, tripelennamine and diphenhydramine did not 
significantly alter the systolic blood pressure of dogs. All the 
compounds in this study did, however, produce minor fluctuations in 
\ 
the blood pressure which are of some interest. 
When phe~iramine was injected intravenously, it produced a 
transient fall in blood pressure, which was followed by a slight 
rise in blood pressure, (Table 19). TMT, a trimethoxy analog of 
pheniramine, caused an immediate, transient rise in blood pressure 
but did not have the hypotensive effect of pheniramine, (Table 21). 
On the other hand, Dma-TMPP, -when injected intravenously into rats, 
elicited an immediate fall in blood pressure but lacked the hyper-
tensive effect of pheniramin~ (Table 20). This compound also has a 
trimethoxy substitution, however, in addition, the pyridyl ring 
found on the parent compound has been replaced by a molecule of 
oxygen. 
An interesting observation was made with the pheniramine analogs, 
TMT and Dma-TMPP, in regard to the blood pressure and tissue studies. 
While these compounds exhibited similar actions on histamine-induced 
contractions (i·~·' they were both weak competitive antagonists of 
histamine), they produced opposite effects on the blood pressure. 
Dma-TMPP had a hypotensive effect and TMT produced a hypertensive 
effect, both of -which were similar in degree to those induced by 
pheniramine. These changes were brought about by approximately the 
same doses of all drugs. It seems likely that the blood pressure 
effects of TMT, Dma-TMPP, and pheniramine are independent of their 
histamine-antagonizing abilities. 
86 
From Table 17, it can be seen that injections of diphenhydramine 
caused a transient decrease followed by a slight rise in blood pressure. 
This diphasic response was also seen by Loew et al. (1946) following 
intravenous injections of diphenhydramine into dogs. Injections of 
TMBD, which is the trimethoxy analog of diphenhydramine, produced the 
same diphasic response in rats as the parent compound, (Table 18). 
'Ihe only noticeable difference between the two compounds was that a 
higher dose of the analog was needed to produce the same response. 
Intravenous injections of tripelennamine induced a transient 
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fall in blood pressure followed by a slight rise in pressure, (Table 22). 
Injections of equal concentrations of De-TMPBZ and TMPBZ resulted in 
a transient drop in blood pressure while injections of higher concen-
trations of the remaining trimethoxy analogs caused a temporary rise 
in the pressure, (Tables 23-27). From the results of the blood 
pressure and isolated tissue studies, it is evident that the actions 
of De-TMPBZ and TMPBZ are very different from the other trimethoxy 
analogs of tripelennamine. 
C. ACTIVITY STUDIES 
The actophotometer was used to evaluate the effects of tripelen-
namine, Mor-TMPBZ, pheniramine, and Dma-TMPP on the locomotor activity 
of mice. This has been shown to be an effective method for measuring 
locomotor activity (Mendillo, 1965). The experimental design used for 
the study was modified after principles outlined by Mendillo in his 
study of the chronic effects of drugs in rats. 
As mice were used in this study and counts were taken for only 
thirty minutes, it was necessary to determine the best method of 
analyzing the data. 'Ihe thirty minute counts for each cage were 
recorded as incremental ten minute and fifteen minute counts, and a 
C value Ci·~·' coefficient of variation, S.D./X x 100%, Snedecor, 1956) 
was computed for the counts in each time interval. 'I'he C values supply 
a measure of the efficiency of each time interval by determining the 
randomness of the data around the mean. Therefore, a low C value 
indicates little randomness in the data and greater efficiency than 
a higher C value. 
The results in Figure 12 show that the counts generated at 0-10, 
0-15, and 0-30 minutes have the lower C values and are therefore the 
most efficient time intervals. The counts generated in the 20-30 
minute and 15-30 minute periods had the higher C values, indicating 
an increased randomness in the data. The mean counts at 0-15 and 
0-30 minute intervals were reported in Tables 28 and 29, because 
they represented the time intervals which best estimated drug action. 
The results in Table 28 show that pheniramine caused a significant 
increase in locomotor activity of mice while the trimethoxy analog, 
Dma-TMPP, had no effect. This stimulatory activity of pheniramine 
had been reported earlier by LaBelle and Tislow (1955), who adminis-
tered pheniramine orally to dogs. 
In Table 29, it is seen that tripelennamine did not have a signi-
ficant effect on locomotor activity in mice, while Mor-TMPBZ signifi- · 
cantly depressed locomotor activity. The depression induced by Mor-
TMPBZ did not appear to be the result of somnolence, since the mice 
were found to be awake at the end of the run and their motor coordi-
nation appeared normal. Results from the Mor-TMPBZ activity experi-
ments indicate that in future studies, this phase of the 'investigation 
should be expanded to determine if this derivative does, in fact, 
possess tranquilizing properties. 
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VI. SUMMARY .AND CONCLUSIONS 
A. The cumulative dose-response technique used in this study was 
a reliable meth0d for determining the histamine-antagonizing abil-
ities of experimental compounds. 
B. The trimethoxy analogs of tripelennamine, pheniramine, and di-
phenhydramine were very weak antagonists of histamine-induced intes-
tinal spasms. De-TMPBZ and TMPBZ were non-competitive inhibitors of 
histamine, while the remainder of the analogs were competitive 
inhibitors of histamine. 
C. The trimethoxy analogs of the above antihistamines did not (with 
one exception, TMBD) elicit diphasic effects on the systolic blood 
pressure, as seen with the parent compounds. None of the compounds 
significantly affected the blood pressure. 
D. Tripelennamine and Dma-TMPP, injected intraperitoneally, did not 
have a significant effect on locomotor activity of mice as measured by 
the actophotometer. Pheniramine, however, caused a significant increase · 
in locomotor activity. Mor-TMPBZ caused a significant decrease in 
locomotor activity and warrants further consideration. 
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